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Abstract 
Background:  
HIV infection and AIDS are characterized by a multitude of symptoms which has not changed since 
the advent of HAART. Based on this reality the World Health Organisation (WHO) recommends 
palliative care to be provided alongside disease specific treatment for all PLWHIV. There are many 
barriers to patients reporting their symptoms and physicians often fail to recognise the symptom 
burden. 
Palliative medicine improves quality of life, relieves suffering, provides good end of life care and 
helps patients and loved ones to come to terms with a chronic progressive disease. 
Namibia is one of the hardest hit countries globally with respect to the HIV epidemic.  No palliative 
care services are available in that country yet. No research has been done to assess the prevalence 
and burden of symptoms amongst PLWHIV. The study serves as a pilot project to address these short 
comings. 
Aim:  
The aim of this study is to assess the prevalence and associated burden of symptoms in patients 
attending an HIV clinic in Swakopmund and local general practitioners’ awareness of the symptom 
burden and assessment in HIV patients. 
Methods 
 This was a cross-sectional descriptive study conducted at the HIV clinic at the State Hospital in 
Swakopmund, Namibia, and amongst general practitioners working in the Erongo region. 
The study was conducted in two parts: 
1) Assessment of symptom prevalence and severity in HIV patients on HAART attending the 
HIV clinic at the Swakopmund State Hospital  
A total of 104 adult patients were recruited using simple random sampling was used to 
recruit 104 adult patients who were interviewed using the MSAS-SF. Demographic data and 
symptoms recorded by the health care professionals during follow-up visits were extracted 
from the patients’ records.  
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2) The evaluation of general practitioners’ perception regarding the symptom burden and 
importance of symptom assessment in HIV patients receiving HAART 
Based on the outcome of the above findings a questionnaire was designed to assess the 
awareness of general practitioners of the burden of disease in PLWHIV.  
Ethical Approval was obtained from the Human Research Ethics Committee of the University of 
Cape Town as well as from the Ethical Committee of the Ministry of Health, Namibia. 
Results 
The median of the sample was 40 years, the median CD4 count 417, and the median number of 
years on HAART was 4. The majority were females (61.5 %) and 66.3% were employed. The mean 
number of symptoms was 5.99 (median 5, SD 4.912). The most common symptoms were of 
psychological nature and pain, cough and peripheral neuropathy were common physical symptoms. 
Median values of TMSAS, GDI and PSYCH were higher in the unemployed and in females. PHYS was 
significantly higher in females. There was no association with the CD4 count. Time on treatment is 
not significantly related to any of TMSAS, GDI, PHYS or PSYCH scores, but younger age was related to 
higher GDI. Patient self-report of symptoms was significantly higher than symptoms recorded by the 
health practitioners during follow-up. Many general practitioners (44%) assume patients on HAART 
to be relatively symptom free, that low CD4 counts are related to symptom burden (84%) and that 
patients will report symptoms if present(76%). 
Conclusion: 
Symptom prevalence and burden is high in this study population despite HAART and there seem to 
be barriers to the reporting of symptoms by the patients. There is evidence of poor symptom 
assessment and symptom control. This highlights the need for palliative care for ambulatory HIV 
patients. 
 
 
 
 
 
 
10 
 
Introduction 
In this chapter the reasons for high symptom prevalence in patients living with HIV (PLWHIV) are 
explored. Definitions for holistic care are provided and the need for palliative care in the 
management of HIV/AIDS is discussed. 
Symptom prevalence and HIV/AIDS 
HIV infection and AIDS are characterised by a multitude of symptoms. In the pre-ART era HIV/AIDS 
was a terminal condition and physicians could only provide palliative care, treating pain and other 
symptoms of advanced disease1. In first world countries HIV specific hospices and specialised 
services arose as a result of the AIDS epidemic2 and in sub-Saharan Africa community based home 
care models were developed3. 
 HIV has now become a chronic illness that can be managed by highly active anti-retroviral treatment 
(HAART)4. It is clear that antiretroviral treatment has greatly improved physical wellbeing in patients 
living with HIV, allowed a return to a high functioning life for many and improved survival; but it is 
still a progressive incurable disease5.  
 Life expectancy and quality of life have improved; but mortality in patients with HIV remains higher 
than average and there is a rise in the number of deaths due to non-AIDS defining illnesses such as 
end stage liver due to Hepatitis co-infection, myocardial infarction and pulmonary diseases6. The 
initial decrease in mortality rates with the introduction of HAART has flattened7 and mortality rates 
are on the rise again amongst socially disadvantaged patients8. 
 HIV infection is symptomatic throughout the course of disease. The primary HIV infection usually 
presents as a flu-like illness that resolves again. This is followed by an “asymptomatic” period. In 
untreated HIV infections symptoms result from disease progression, decreased immunity and the 
resultant opportunistic infections. The latter can cause multiple symptoms such as mouth sores, 
neuropathic pain, breathing problems and gastroenteritis that can occur concurrently9.  
Pain and other chronic symptoms such as fatigue, anorexia, nausea and vomiting, dyspnoea and 
diarrhoea were common in the pre-HAART era10 and still are today11,12. Prevalence is high regardless 
of CD4 counts, lack of opportunistic infections or the presence of HAART13. Only a third of these 
symptoms are detected by the treating physicians13,10.  
There is a high morbidity due to the disease itself and its co-morbidities. Many patients still present 
with advanced disease.  The multi drug combinations are often toxic and associated with many side 
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effects13.  There are more medical co-morbidities than come with normal ageing9. Cardiovascular 
disease, renal failure, liver cancer and brain impairment manifest more frequently as HIV treatment 
is started earlier8. HIV related malignancies have not declined with the use of HAART14. There is a 
higher incidence at a younger age at diagnosis of non-AIDS defining cancers8. 
Symptoms are subjective experiences and not only depend on physiological processes but also on 
the patients’ interpretation thereof9. Most patients on HAART still remember the days when ART 
was not available and have seen or known people die of AIDS and this results in anxiety about their 
own health. New or persistent symptoms may be associated with treatment failure and fear of dying 
and increasing distress. 
Anxiety about the treatment and the outcome, stigma, disturbed interpersonal relationships, fear of 
disclosure and secrecy are common psychosocial stressors, which amongst others result in a high 
prevalence of depression in patients living with HIV. That in turn can lead to worsening physical 
symptoms or somatisation and treatment non-adherence9 and virological rebound15. 
The prevalence and burden of symptoms in PLWHIV is similar to that seen in other life threatening 
chronic illnesses. Based on that the World Health Organisation (WHO) recommended palliative care 
to be provided alongside disease specific treatment for all PLWHIV12,16,16. 
 
Definitions and declarations 
The World Health Organization defines palliative care as “an approach that improves the quality of 
life of patients and their families facing the problems associated with life-threatening illness, 
through the prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosomatic and spiritual”17. The 
WHO promotes palliative care as essential in HIV care from diagnosis to the end of life because of 
the high prevalence of symptoms throughout the disease trajectory18. A team, ideally comprised of 
nurses, social workers, doctors, spiritual counsellors and, in the African context of HIV/AIDS, 
community care givers, assists patients, their care givers and families3. 
Similarly, not specific to life threatening illnesses, holistic medicine is defined by the Canadian 
Holistic Medicine Association19 as “ a system of health care which fosters a cooperative relationship 
among all those involved, leading towards optimal attainment of the physical, mental, emotional, 
social and spiritual aspects of health”.  
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These definitions embraces the concept of “total pain” defined by Cicely Saunders, the founder of 
the modern hospice movement, as the suffering that encompasses all of a person’s physical, 
psychological, social, spiritual and practical struggles20. 
To integrate palliative care into existing health care systems the WHO used the framework of 
education, government policy and drug accessibility to develop a public health strategy21,22. A public 
health approach aims to improve health and quality of life of everyone in a community by 
introducing cost-effective and evidence-based interventions22. Palliative care is such an intervention 
which unfortunately is not available to a large proportion of the world’s population22.  At a congress 
in Cape Town for African palliative care trainers a consensus statement was drawn up, bearing in 
mind the many unmet needs of patients living with HIV/AIDS, cancer and other life threatening 
diseases in Africa. The Cape Town declaration23 (Box 1) is based on the strategic pillars of the WHO. 
Box 1: Cape Town Declaration23 
The World health assembly adopted the first-ever resolution on palliative care in 201424, calling for 
the integration of palliative care into national health services. The resolution clearly outlines 
recommendations to improve access and availability of hospice and palliative care, which include the 
integration of hospice and palliative care into national health services, budgets, and training in 
palliative care into the curricula for health professionals. 
Palliative Care and HIV/AIDS 
The “medicalisation of HIV/AIDS”25 resulted in overlooking issues related to treating a progressive, 
incurable and ultimately fatal disease. The interest in new therapeutic options and in quantifying the 
response to treatment should not obscure that fact that there is a need for palliative care at all 
stages of HIV disease4. Symptoms are often unrecognised, either because health care providers do 
not ask or because symptoms are considered “subclinical”13 - because they are not measurable or 
not obviously related to disease or disease progression. Unaddressed physical, psychological and 
1. Palliative Care is a right of every adult and child with a life-limiting disease.  
2. Appropriate drugs, including strong opioids, should be made accessible to every patient 
requiring them in every sub-Saharan country and at all levels of care, from hospitals to 
community clinics and homes.  
3. The establishment of education programs at all levels of the learning continuum; for all 
formal and informal caregivers, including medical and nursing trainees, community workers, 
volunteers and informal caregivers. 
4. Palliative care should be provided at all levels of care: primary, secondary and tertiary. While 
primary care is emphasized, secondary and tertiary level teams are needed to lead and foster 
primary level care. This necessitates career opportunities for secondary- and tertiary-level 
palliative care professionals. 
13 
 
social symptoms, besides negatively influencing quality of life, have potentially severe clinical 
implications such as decreased treatment adherence, subsequent treatment failure, resistance and 
increased infectiousness as well as increased morbidity and mortality26. 
Based on areas of evidence in HIV/AIDS epidemiology, Harding et al25 spelled out 5 key areas 
highlighting the continuing need for palliative care in PLWHIV: i) prevalence of symptoms, ii) higher 
mortality rates than in non-infected people, iii) additional co-morbidities associated with prolonged 
survival, iv) HIV related cancer risk and v) late presentation.  
Patients require integrated pain and symptom control along-side HAART. Palliative medicine 
improves quality of life, relieves suffering, provides good end of life care- including addressing 
treatment failure and withdrawal of HAART if futile- and helps patients and loved ones to come to 
terms with a chronic progressive disease25. 
Namibian facts 
Namibia is one of the hardest hit countries globally with respect to the HIV epidemic, the prevalence 
ranging from 4 to 33%, averaging 13.5%27. In 2003 with support of the Global Fund and the 
President’s Emergency Plan for AIDS Relief (PEPFAR) the Namibian government implemented an 
antiretroviral program in Namibia’s public health facilities28. After piloting free prevention of 
mother-to-child-transmission the antiretroviral program has now been rolled out to the entire 
country, with 90% of patients in need of antiretroviral treatment (ART) receiving it28. 
The AIDS epidemic was the impetus for nongovernmental organisations (NGO) to start home based 
care programs, which for a long time were the only services in Namibia approximating palliative 
care. A recent pilot study (to identify priorities and preferences of the Namibian public for end-of-life 
care) in form of street survey in Windhoek, the capital of Namibia, revealed amongst other things 
that a hospital and not a hospice or palliative care unit was the preferred place of death for the 
majority of participants29. This was more likely due to being unfamiliar with such units, which are not 
available in Namibia, than a true preference for hospital care. 
The Namibian constitution does not have a clear right to health, but it states that “general rules of 
public international law and international agreements binding upon Namibia become part of the law 
of Namibia”30. One of these signed agreements is the International Covenant on Economic, Social 
and Cultural Rights (ICESCR). The ICESCR not only asserts that “the State Parties to the present 
Covenant recognize the right of everyone to the enjoyment of the highest attainable standard of 
physical and mental health”, but also emphasises the need for “attention and care for chronically 
and terminally ill persons, sparing them avoidable pain and enabling them to die with dignity”21. 
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In 2007 the African Palliative Care Association (APCA), sponsored by the United States Agency for 
International Development (UNAID)/Namibia, started to scale up palliative care in Namibia. It has 
now been integrated into the HIV and AIDS national health policy, but unfortunately has not been 
implemented yet. The 2014 National Guidelines for ART include a paragraph which only advises on 
regular monitoring for side effects of treatment and for progress of disease or presence of 
opportunistic infections; no advice is given as to the treatment of possible symptoms31. 
In public health services it is difficult to address all the determinants of poor health. Recently 
Namibian clinics have become nurse run. Treatment initiation, TB screening and basic symptom 
control are managed by trained registered nurses, who are, however, not allowed to prescribe 
scheduled drugs, including morphine. Only difficult cases are referred to the medical officers. It has 
been shown that personalised treatment with good doctor-patient concordance improves quality of 
lives and decreases symptom burden and distress32. Patients dependent on public health services do 
not have a choice of health care provider and might get treated strictly according to treatment 
guidelines, but have little opportunity to discuss treatment options. 
 With more than 11 indigenous languages being spoken in Namibia and with many foreign health 
professionals employed in the public service, language and cultural barriers to effective health care, 
amongst others, are immense. However, good symptom control should still be a priority. No studies 
could be found that assessed the symptom prevalence in patients living with HIV in Namibia.   
It is assumed that the symptom burden of the Namibian people living with HIV is not less than 
elsewhere. The aim is to document their experience using the short form of the Memorial Symptom 
assessment scale (MSAS-SF) and comparing that to their health care providers’ recognition thereof. 
By doing that it is hoped to create awareness amongst health care providers about the extent of the 
problem, and to encourage patients to report their symptoms, even if not specifically asked about 
them. 
In the introduction the symptom prevalence amongst PLWHIV and the need for palliative care was 
discussed.  The literature review below focuses on studies assessing symptom prevalence and 
burden amongst PLWHIV worldwide. The burden of ART is discussed as well as barriers to symptom 
control. Literature discussing the need for and the effectiveness of palliative care is also included. 
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Literature review 
The aim of the literature review was to find published studies done and data collection tools used to 
document symptom prevalence and burden of patients living with HIV/AIDS. Reasons for poor 
symptom control were also sought. Special interest was shown towards studies done in southern 
Africa, particularly Namibia and South Africa, as these two countries have similar health systems and 
treatment guidelines for PLWHIV.  
Electronic databases were chosen based on the likelihood of yielding useful information. Via EBSCO 
Host the following data bases were searched simultaneously during the period June 2013 to July 
2015: Medline, Africa-Wide Information, CINAHL, SocINDEX, and PsycARTICLES all from 1990-2015.  
Google scholar and Pubmed, even though it mainly accesses Medline, were also searched. 
MeSH (medical subject headings) terms used in various combinations and in union with 
HIV/AIDS/HAART were symptom/pain/prevalence/burden/assessment/recognition/under-
treatment, pain. These terms in addition to “knowledge” and “barriers” in union with 
clinician/healthcare provider/physician with or without HIV/HAART were searched to find studies 
exploring reasons for under-treatment of symptoms in general and in PLWHIV specifically 
With the advent of HAART quantitative aspects of HIV management and monitoring became more 
important than the human dimension of the disease as described by Selwyn and Arnold1. Despite 
decreased morbidity and mortality in patients who can access treatment, the symptom burden has 
not been eliminated. 
Symptom prevalence in the Pre-/ Early HAART era 
i) International studies 
It is well known that patients living with HIV in the pre-HAART era were often symptomatic and had 
a high prevalence of pain syndromes as described amongst others by Vogl et al 33. These studies are 
included as they give a good foundation for symptom assessment and management. 
In the early days of ART availability, as part of an ongoing study of pain and quality of life of 
ambulatory AIDS patients in New York City, Breitbart et al assessed the presence and intensity of 
pain, associated factors and the impact on quality of life 10,34. Despite being published in 1996 it is 
still quoted frequently in current literature 35,36,37. The authors conducted an extensive literature 
review which highlights the scope of the problem of pain in AIDS patients, but all studies included in 
the review were either retrospective studies or used small patient samples. The Breitbart study was 
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a systematic prospective cross-sectional survey of a large diverse patient population (438 patients) 
and used validated data collection tools.  It was one of the first studies to use the short form of the 
memorial symptom assessment scale (MSAS-SF), previously validated for cancer patients38, to 
measure physical and psychological distress in AIDS patients. In addition, the brief pain inventory 
(BPI) -which consists of a number of questions regarding pain, its severity and its interference with 
daily life, as well as rating the pain relief obtained from treatment39- the Karnovsky Performance 
scale and the AIDS specific physical symptom check list were used. Only half of the patients were on 
some antiretroviral treatment, and 77% on treatment for opportunistic infections. Pain was reported 
by 62% of patients, of which 50% had severe pain. This was comparable to pain intensity typically 
experienced by cancer patients10.  On the MSAS an average of 17.1 symptoms were reported and the 
average physical distress score rated as 1.2. Pain was excluded from the calculation of the latter to 
show that the physical distress score was directly related to the presence of pain. The presence of 
pain was associated with the number of concurring HIV related symptoms, lack of ART, disease 
progression and current treatment for HIV related diseases. The presence and intensity of pain 
significantly influenced the psychological distress and the quality of life 34.  
In the same ongoing study the Pain Management Index (PMI), as derived from the BPI was used to 
assess whether analgesic therapy corresponded to the type and severity of pain according to the 
WHO guidelines40. This assessment was based solely on patient self-report and not validated by 
independent chart review or physician contact. Nevertheless, a negative PMI for over 80 % of 
patients gives a strong indication that pain is not adequately controlled. Interestingly, women, 
poorly educated people and patients infected by HIV due to intravenous drug use, were more likely 
to receive inadequate pain control. The authors40 suggested the following barriers to providing 
adequate analgesia: poor knowledge of physicians regarding pain and management in HIV disease, 
stigma and discrimination associated with HIV disease and patient related barriers. The latter, 
including fear of addiction, side effects of treatment and beliefs about the illness, was shown to play 
a big role in under-treatment of pain in HIV infected patients41. 
ii) Studies in Southern Africa 
Very little could be found about studies done in southern Africa on HIV/AIDS symptomatology in the 
pre-HAART era. 
The study done by Norval 42 in 2004 seems to have been the first to investigate the symptom 
prevalence in HIV patients in South Africa. No literature review is evident, but similar studies done 
elsewhere were mentioned in the discussion. The study included 103 adult patients with WHO stage 
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4 AIDS, registered at the SOWETO hospice in Johannesburg. They were questioned on 26 symptoms 
and sites of pain. It is not clear how the list of symptoms were derived at. No sample size calculation 
was reported. But the study clearly showed that pain was highly prevalent (98%) and reported as the 
worst overall symptom in a third of patients. The commonest sites for pain were the lower limbs. 
Other common symptoms were weight loss, loss of appetite, low mood, weakness and dry skin. 
Despite its shortcomings the study highlighted the need for palliative care throughout the HIV 
disease trajectory. 
Symptom prevalence and burden in the current treatment era 
i) International studies: 
In 2012 Merlin et al 43 achieved their aim of determining the prevalence and severity of symptoms 
and related risk factors in a population of ambulatory HIV patients. This study included 156 patients 
(the sample size was not elaborated on) that were selected from a large clinical cohort from the 
University of Pennsylvania’s centre for AIDS Research (CFAR). Although not specifically mentioned, it 
was assumed that all participants were receiving HAART, as all of them had a viral load less than 
1000 copies/ml. The BPI and MSAS-SF were used as data collection tools. Risk factors for the 
presence of pain were assessed by multivariate analysis. These factors assessed were: psychiatric 
illness, intravenous drug use, tobacco use, race, CD4 category and viral load. The types of HAART 
used weren’t mentioned and not included in the analysis. Psychiatric illness and IV drug use were 
associated with higher MSAS subscale scores and patients with psychiatric illness were 40% more 
likely to have pain. The median number of symptoms was 8; common physical symptoms that also 
caused high distress were pain, lack of energy and tingling of hands and feet. More than half of the 
cohort experienced 4 out of the 6 psychological symptoms. 
The researchers also did a chart review on the day of the interview to see whether pain was 
mentioned in the participants’ progress notes and what treatment had been provided. Of the 
patients who reported pain during the study, this was documented in only 67% of cases, severe pain 
being more likely to be documented. Half of the patients receiving analgesics reported relief of pain. 
Pain is a common symptom in PLWHIV36 and many reports suggest that anxiety44,15,26, depression45-47 
and fatigue15 are common yet underreported36. 
A recently published review by Parker et al48 focuses on the prevalence and characteristic of pain in 
PLWHIV, factors contributing to pain and pain management. Populations from low-income countries 
and females were found to be underrepresented in the studies. Prevalence rates of pain are 
between 50 and 67% throughout all stages of the disease and have not diminished over the 30 years 
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spanning the studies reviewed. It was noted that despite increasing awareness of the problem 
under-management persists .The comment by Harding et al49, discussing some draw backs of the 
review, more clearly spells out associations with pain and symptom burden: “of sexual risk taking, 
poor adherence to ART, treatment switching, viral rebound, poor quality of life and suicidal 
ideation”. Parker50 responded by reiterating that the time has come to test and develop strategies to 
improve pain assessment and management rather than to identify and describe the problem of pain 
in PLWHIV. 
ii) Studies in Southern Africa 
Harding et al51 were the first to report on the prevalence, burden and correlates of physical and 
psychological symptoms in HIV patients receiving palliative care in sub Saharan Africa. Researchers 
recruited 224 patients, 192 from South Africa and 32 from Uganda. The reason for the study sites in 
different countries and the choice of the sample size is not clear. The data collection tool was the 
MSAS-SF and additional physical symptoms, determined to cause distress in another study from 
Uganda, were added. It is of note that the mean number of symptoms was 18; the most prevalent 
symptoms were pain, feeling sad, feeling drowsy, worrying and lack of energy. Symptoms rated 
highest in severity were hunger, pain, loss of weight, numbness and lack of energy. All the MSAS 
subscales showed high levels of distress. Women and patients with poor physical functioning, as 
assessed by the Eastern Cooperative Oncology Group (ECOG) functional status score experienced 
higher symptom burden and distress. Being on ART did not change the symptom burden, 
emphasising the need for palliative care despite provision of ART. 
It was hypothesised that prevalence of symptoms would be even higher in HIV patients not receiving 
palliative care; but in their discussion they mentioned a similar study done in Uganda by Wakeham52 
on HIV patients without access to palliative care in which symptom prevalence and burden were 
slightly less. These participants all had a CD4 count of less than 200 cells per micro litre and none 
were receiving ART. In the Harding study under discussion too few CD4 counts were available to 
make any useful comparisons. 
Two papers were published in the SAMJ on a study done in 3 public sector HIV clinics in 
Johannesburg, South Africa. In the first paper Farrant et al11 used the MSAS-SF to determine the 
prevalence and burden of symptoms in 365 patients (sample size calculation not included) of which 
98% were on HAART. All 4 psychological symptoms (sad, irritable, worrying, feeling nervous) were 
amongst the ten most prevalent. Common physical symptoms were numbness and tingling in hands 
and feet, sexual problems, pain, “I don’t look like myself” and lack of energy. 
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In the more detailed second paper describing the study conducted by Farrant et al53 the 7 patients 
not receiving HAART were excluded from the study population. In addition to using the MSAS-SF, the 
physical performance for each participant was scored using the Karnofsky Performance scale 
(0=dead, 100=normal). A mean score of 90 indicated a high level of functioning but did not mean 
patients were symptom free. 
This paper focussed on “Maintaining wellbeing for South Africans receiving ART: The burden of pain 
and symptoms is greater with longer ART exposure” and also explored additional associations of 
symptom burden with independent variables. Associations of the MSAS subscales were tested 
against the independent variables of age, gender, WHO stage, current CD4 count and count at start 
of treatment, current viral load, years on treatment and whether treatment was switched. 
Treatment combinations were not recorded. There was a consistent relationship between worse 
symptom indices and greater number of years on treatment. In addition WHO stage was associated 
with higher symptom burden and higher global symptom and psychological distress. Female gender 
and increased age were associated with higher physical distress scales. 
In a very similar study done in Uganda, Namisango et al54 investigated whether symptom burden is 
associated with treatment status, CD4 count and clinical disease stage. Patients with a low 
Karnovsky performance status had more symptoms and higher distress; psychological distress was 
high for patients with WHO stage 4 disease. ART and CD4 were not associated with symptom 
burden, but in contrast to the study above, men had higher symptom burdens. Symptom burden 
was not affected by level of education. 
Psychological distress 
i) International studies: 
In a recent systematic review of literature Lowther et al26 assessed the prevalence of depression, 
anxiety and experience of stigma in patients on HAART. The review was performed following the 
PRISMA (Preferred reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the 
Loney quality appraisal tool was used to evaluate the paper quality. The more specific search items 
such as “depression”, “anxiety” and “worry” were used but no less specific terms such as 
“psychological distress”. Depression was defined as decreased mood, loss of interest or enjoyment 
and decreased energy; anxiety as excessive irrational fear or dread.  A large number of different data 
collection tools (34) were used in the various studies, the most commonly used were the Beck 
Depression Index, Centre for Epidemiological Studies depression tool CES-D) and the Hospital anxiety 
and depression scale (HADS). However, some collection tools used, as for example the MSAS, 
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measure psychological distress, which does not necessarily amount to the diagnosis of depression or 
anxiety. A mean point prevalence of 33.6% was found for depression and 28.4% for anxiety, with 
higher values being found in low income countries. The figures, despite the heterogeneous sample 
characteristics, assessment tools and methodologies, were then compared to prevalence of 
depression/anxiety in 1) the general international population and 2) patients with other chronic 
conditions. It was concluded that depression and anxiety are highest amongst PLWHIV. Up to 80 % 
of patients experienced stigma. It was hypothesised that as stigma is associated with psychosocial 
distress, this could be a reason for the high depression/anxiety prevalence. 
ii) Studies in Southern Africa 
Kagee55  reported on the prevalence of sub-clinical psychological distress amongst patients living 
with HIV, hypertension and/or diabetes. The study was not included in the above review. The 
participants were recruited from public health clinics in the Western Cape and were divided into 4 
subsamples: patients living with hypertension (85), with diabetes (25), with both hypertension and 
diabetes (14), and with HIV (85). Sample size calculations were not included. The subsample of HIV 
patients was younger than the others, but almost all patients lived in relative poverty. The Hopkins 
Symptom Checklist (HSCL-25), a measure of emotional distress, was administered to all sub-samples. 
The scoring system was not explained, but the scores for all 4 groups were high and did not differ 
significantly from another. 
Symptoms: Treatment or disease? 
It is well known that poor adherence to HAART compromises its efficacy as described by Stone et 
al56. Adherence, in turn, is amongst others influenced by patient-reported symptoms and medication 
side effects as reported, amongst others by Ammassari57, Cooper58 and Berg et al59. 
Johnson et al60 investigated not only the prevalence and burden of symptoms of 109 patients on 
HAART but also whether these were perceived as disease or treatment side effect related 
respectively. The validated HIV symptom index61, similar to the MSAS tool, records the presence of 
20 symptoms and “the amount of bother” on a Lickert scale 1-4. In this study the list was extended 
to 38 symptoms, apparently to capture a wider range of problems. The need for this, however, is not 
evident as some symptoms have been duplicated (e.g. upset stomach and diarrhoea). On the 
symptom checklists participants of the study indicated whether they attributed the symptom to the 
disease, the treatment, both or other causes. Subscales of the SF-36, a validated tool to assess 
quality of life and functioning, helped to determine quality of life with respect to general health, 
physical and social functioning respectively.  
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 Upset stomach, nausea and vomiting, constipation, and alterations in taste sensation were most 
commonly attributed to side effects of treatment, whereas tender or enlarged lymph nodes/glands, 
night sweats, unintentional weight loss, fever, and loss of strength  to the disease itself.                                                        
 Impact of side effects, symptoms, and both were associated with impaired physical and social 
functioning. “In contrast to disease-related problems, symptoms attributed to side effects were not 
related to perceptions of general health.  HIV-positive persons taking HAART make distinctions 
between symptoms of disease and side effects of treatment”.  
The participants were mostly male (80%) and had been on HAART for an average of 9 years. 
Although the results may not be generalizable, the study highlights the need to assess patients 
beliefs regarding the cause of their physical problems, as perceived disease and side effect-related 
symptoms have significant and unique associations with quality of life and with adherence to 
treatment57. 
In a similar study done in Germany, Kremer et al62 examined gender differences in the causal 
attributions of symptoms. They found that men were more likely to attribute symptoms to the 
disease and were motivated to maintain a treatment regime, whereas women were risking non-
adherence or switching treatment regime in order to avoid side effects. 
As part of a study exploring the wider experience of living amongst gay men with HIV in the UK, 
Harding et al35 assessed the symptom prevalence and burden as well as the association with the use 
of HAART in that very specific patient population. This was an online survey of 347 men, of which 
57% were on HAART, recruited via gay websites, email lists and flyers at HIV clinics. It is not clear 
whether this really included all the HIV clinics in the UK. The MSAS-SF tool was used for the first time 
in a patient population with less advanced HIV disease and on HAART.  
As in other studies symptom prevalence was high, especially for psychological symptoms, regardless 
of the use of HAART. Physical symptom prevalence was higher in HAART users. Of the 14 symptoms 
that were significantly more frequent amongst HAART users, most could be related to treatment 
side effects. HAART combinations of study participant were not specified. Of the independent 
variables age, years living with diagnosis, being on treatment (time on treatment was not 
considered), CD4 count and viral load, only the use of HAART was associated  with higher number of 
symptoms and global (borderline significant) and physical distress indices. A lower CD4 count was 
weakly associated with higher global distress. Although not mentioned in the discussion of the study, 
the physical distress index was less than one for both groups of patients, which implies (see 
Methodology, MSAS-SF) that although present, the distress is not very significant. 
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The authors describe limitations of the study but these do not detract from the message that 
antiretroviral therapy is associated with symptom prevalence and burden. 
In a similar study done in San Francisco, Lee et al63 investigated how personal characteristics might 
influence symptom experience. The study sample was more ethnically diverse and predominantly 
male. They also found that ART users had a larger symptom burden than patients not yet receiving 
treatment. The MSAS distress scales, however, were lower than those measured in HIV/AIDS 
patients in the pre-HAART era10,64. The finding that the type of antiretroviral regime had no effect on 
the symptom burden was not validated. Nowhere in the paper were the ART combinations 
mentioned. 
International12 and local31 HIV treatment guidelines now recommend the combination of Efavirenz 
(EFV), Emtrictabine (FTC) and Tenofovir (TDF) as first line regime in treatment-naïve HIV patients. 
Edelman et al12 compared the symptom experience of patients on EFV/FTC/TDF with those on other 
treatment combinations and how that affected health related quality of life. The rationale of the 
research was to study an older HIV population with co-morbid disease, in this case veterans (1759 
participants) that are part of the Veterans Aging Cohort Study (VACS). The study population, largely 
represented by black males, was also supposed to better reflect a routine clinical population than 
those participating in randomised controlled trials. The average age of these men was 54. Co-morbid 
disease was rated by the VACS index, which is a prognostic score for all-cause mortality and 
incorporates data on age, HIV and non-HIV biomarkers. However, co-morbid diseases expected in 
that age group such a cardiovascular disease and the respective treatment were not alluded to, and 
might have influenced the symptom experience. Even though the population was slightly older, the 
average time on HAART was only between 2-3 years. They did, however, show clearly that symptom 
burden, as assessed by the HIV symptom index, was less in patients on EFV/FTC/TDF and that they 
had an improved quality of life, as measured by the SF-12. 
Underestimation, under-recognition, underreporting and under-treatment of symptoms 
i) International studies 
The “under-recognition and under-treatment of pain and other symptoms” is often stated and work 
done in the pre-HAART era by Breitbart et al40 , as discussed before, and Fontaine, Larue and 
others65,66 are still the most frequently quoted to substantiate the statement39,53,37: 
In the first of the two reports by Larue, Fontaine and others65 describing a large study done in 
France, prevalence and burden of pain was assessed using the BPI. Participants also had to rate their 
quality of life, but it is not clear what they were to base it on. Treating physicians were asked to 
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record the presence and rate the severity of pain, identify the source of pain and describe the 
treatment provided. Pain severity was underestimated in 52% of patients; underestimation being 
less likely in less severe pain and when a source for pain could be identified. 
 Based on the WHO guidelines a pain management index (PMI) was calculated to assess the 
appropriateness of analgesic treatment with respect to the severity of pain. The PMI was initially 
validated by Cleeland et al67 amongst patients with metastatic cancer. When the PMI was based on 
patients’ reports of pain severity 85% of patients were under-medicated, when based on the 
physicians severity assessment there were still 70% with negative prescription adequacy index 
scores. 
The second paper by Fontaine et al66 concentrated on the physicians’ symptom recognition in HIV 
patients. A list of 16 physical and psychological symptoms common in HIV/AIDS was submitted to 
the patients, who rated each symptom according to its presence and severity. The same list was 
presented to the physicians and then symptom recognition rates and physician-patient agreement 
rates were calculated. Agreement rates ranged from 52% to 84%, with symptom recognition being 
better in ambulatory than inpatients and better in patients with poorer Karnofsky scales. Treatment 
side effects were not more likely to be recognised nor were symptoms amenable to treatment. In 
the discussion it was suggested that ambulatory patients might have been more verbal in voicing 
their complaints than the sicker inpatients. It was also suggested that the low recognition rates 
might have been exaggerated by poor recall bias. It is also possible that the symptom recognition 
was probably higher than the norm as physicians were more aware due to the study. 
Edelman, Gordon and Justice published a similar study in 201116, but the work by Fontaine et al66 
was not included in the literature survey. The title “Patient and Provider-reported Symptoms in the 
Post-cART Era” is misleading as the term post-cART era is confusing and seems to imply up-to-date 
findings. It was, however, a secondary analysis of data collected from the Veterans Aging Cohort 
Study (VACS), an all male study, in 1999. The fact that 87% of participants were on HAART was only 
mentioned in the discussion and there was no mention about the type of treatment received. 
Both patients and their health care providers were presented with the well validated HIV symptom 
index61. Patients rated the presence and burden of symptoms on a 5 point Lickert scale, while 
providers only indicated the presence/absence of these symptoms in the past 4 weeks. Health 
related quality of life (HRQOL) was assessed using the SF-12 and data regarding hospitalisation and 
mortality were collected from electronic medical records. Relationships between reported 
symptoms and quality of life, hospitalisation and survival respectively were assessed. They found, for 
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example, that patients that reported diarrhoea were less likely to die. No sample size calculations 
are available to prove that the percentage of participants that died (29%) was high enough to draw 
that conclusion. Patient reported symptoms that had a statistically significant correlation with 
outcome were compared to provider recognised symptoms. Using patient-report as gold standard, 
provider agreement was poor, with kappa scores less than 0.4 for all. 
Despite certain shortcomings, the authors clearly showed that the reliability of provider recognised 
symptoms is poor and make a case for using tools to improve symptom recognition and 
management. 
ii) Studies in Southern Africa 
In a pilot study done in a district hospital in Durban, South Africa, Narasimooloo et al39 investigated 
the prevalence, severity, recognition and adequacy of management of pain in a group of medical in-
patients. This was adequately described in the abstract. Ethical approval was obtained from the 
relevant ethics committees. A convenience sample of 100 adult patients with a HIV related diagnosis 
was chosen for this descriptive study. The short form of the BPI was used to assess prevalence and 
severity of pain and its effect on the quality of life. By reviewing the patients’ medical charts the 
documentation of pain and the treatment prescribed were assessed. The latter was compared to the 
severity of pain reported and the PMI calculated.  A large proportion of patients (70%) had a CD4 
count less than 200 and despite ART being available for free at government clinics, only 34% of the 
patients were on ART. The majority of patients (91%) reported the presence of pain, of which 70% 
was documented in the charts. A third of those patients reporting pain received no analgesics. In 
66% of patients a negative PMI score was calculated, indicating inadequate analgesic treatment. This 
study again shows that pain recognition and management is poor. A strong case is made to use pain 
assessment tools in clinical practice and to explore barriers to adequate pain management. 
 Barriers to symptom control 
i) International studies: 
 Clinicians’ under-recognition and poor assessment often leads to under-treatment of symptoms and 
subsequent decrease in quality of life; but under-reporting and reticence to take medication also 
interferes with symptom control. Clinical assessment is more likely to focus on the disease and 
markers of disease management than on managing symptoms according to patient experience and 
symptom burden as reported by Resnik et al68. 
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In order to determine factors preventing cancer patients from reporting pain and following 
treatment recommendations Ward et al69 designed and validated a self-report  Barriers 
Questionnaire (BQ), which has since also been used in other studies70,41. The following 8 concerns, 
based on previous literature, were thought to be barriers and the extent to which patients agreed 
with these concern was calculated: a) fear of addiction, b) concern about tolerance, c) concern about 
side-effects, d) fatalism, e) desire to be a “good” patient; i.e. not to annoy the physician, f) fear of 
distracting the physician from treating the disease, g) interpreting pain as disease progression, h) 
fear of injections. 
Pain severity, adequacy of management, quality of life, as well as age, gender and level of education 
were compared to the BQ subscales. Patients who were under-medicated had significantly higher BQ 
scores. The most important finding was that many patients have misconceptions about using 
analgesics and that a large proportion of patients agreed that”good patients avoid talking about 
pain”. In the discussion the importance about good communication and addressing concerns before 
patients complain of pain is spelled out. The same would be true for any symptom management. 
Breitbart et al41  were the first to assess patient-related barriers in the management of pain in AIDS 
patients. The authors modified the Barriers Questionnaire by adding the belief that pain medication 
might impair immune function (a concern that is also increasingly seen in cancer patients70) as well 
as the fear that analgesia impairs the ability to monitor illness symptoms. Fears of addiction and of 
side effects to opioids were the most frequently endorsed concerns. Higher BQ scores were found 
with higher total MSAS scores and were associated with under-treatment. They also came to the 
conclusion that patient-related barriers to symptom management add to the likelihood of under-
treatment of AIDS related pain. 
Breitbart et al71 also assessed clinicians’ perceptions of barriers to adequate pain management in 
patients living with HIV. Health care providers attending continuous education symposiums in 5 
cities in the USA constituted a convenience sample for this study. The questionnaire packets they 
received consisted of i) demographic and clinical practice information, ii) questions that evaluated 
knowledge and attitudes with respect to pain management and iii) sixteen questions regarding 
perceived barriers to pain management. It is not clear how this list of barriers was derived at. 
Summary variables were created from the questions assessing experience in managing pain in AIDS 
patients, knowledge of the principles of pain management and attitude towards pain management. 
Higher scores in “attitudes” reflected more liberal attitudes toward pain management, including less 
avoidance of prescribing opioids. Associations of these variables were then tested against the 
barriers questions. Lack of knowledge of pain management, reluctance to prescribe opioids and 
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concerns about drug abuse were the most frequently endorsed concern, whereas patients’ 
reluctance to report pain or to take opioids was less often seen as a barrier. Clinicians with more 
knowledge regarding pain management perceived patients’ reluctance to report pain and excessive 
state regulations of prescribing analgesics as barriers, whereas the more experienced clinicians 
perceived very few of the suggested barriers as of concern. As these were only assessments of 
clinicians’ perceptions of possible barriers there is no proven causal relationship to poor pain 
management. 
The aim of a systematic review by Harding et al72 was to identify inequalities in HIV palliative care 
and the associated barriers to access to such care. Although the introduction mentioned the host of 
symptoms and morbidities associated with HIV disease and HAART, the review mainly looks at 
terminal care. Search terms included terms representing all care models that include palliation. 
These were intersected with the union of (HIV/AIDS). Terms such as “barriers” or “unmet needs” 
were not included. The information gained was then assigned to barrier and inequity categories of 
patient, clinician, service and disease factors. Patient factors included barriers such as poverty, 
reluctance to address end-of-life issues and acceptance of suboptimal analgesia; lack of adherence 
to protocols, inadequate communication, fear of analgesia misuse/abuse and reluctance to address 
end-of-life issues were amongst barriers assigned to clinicians. Curative focus, lack of access to 
specialist pain management, stigma and discrimination were service factors in need of improving. 
 Land et al73 looked at barriers to underreporting from another angle. They assessed what 
encourages or discourages PLWHIV from completing questionnaires by interviewing ten HIV patients 
attending a clinic in Birmingham. The importance of privacy was stressed; at the same time there 
were anxieties about missing the place in the queue at the clinic if one left to a separate location to 
complete the questionnaire. If patients were unsure about confidentiality and anonymity sensitive 
or personal information would not be disclosed. Questionnaires had to be quick and easy to 
complete and the aims stipulated clearly. Completing questionnaires only seemed worthwhile if 
assurance was given that and how it would improve future clinical practice. 
ii) Studies in Southern Africa 
In a more recent study done by Bogart et al74 at a semi-private hospital in Durban barriers to care 
among people living with HIV in South Africa were investigated. Many patients are lost to follow-up 
after diagnosis and before ART is initiated. Qualitative data collected by semi-structured interviews 
from individual patients and focus groups were contrasted to those collected by similar interviews 
from healthcare providers. Stigma was a barrier to care endorsed by both groups. Patients had 
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concerns about ease of access to clinics, including long waiting times, as well as a non-caring attitude 
of the healthcare providers. The latter under-recognised patient dissatisfaction and it is fairly clear 
from that small study, that better communication (and resultant better understanding of concerns) 
is needed to facilitate patient satisfaction and retention in HIV care.  
Palliative care and HIV/AIDS 
i) International studies: 
In a narrative review, which is an excellent work of reference for every health care provider dealing 
with PLWHIV, Selwyn7 describes why and how palliative and disease-specific treatment for HIV 
should co-exist. Common symptoms and specifically pain syndromes and their aetiologies are 
discussed. Disease and symptom-specific interventions as well as possible drug interactions are dealt 
with. The potential risks and benefits of HAART in late stage HIV disease and the specific 
psychosocial issues for palliative care in the era of HAART are elaborated on. It is made clear that 
palliative care interventions are an important part of routine care of all HIV infected persons. 
In a similar more recent review Fausto and Selwyn44 more specifically discuss the needs of patients 
with advanced HIV disease in the current era of accessible HAART. The article reviews prognostic 
indicators of late-stage AIDS, trends in opportunistic infections, AIDS defining and non-AIDS defining 
malignancies and liver disease. It helps primary health care providers to identify patients that should 
be considered end-stage.  The chronic disease status of the HIV infected as a result of HAART 
management and also the earlier onset of diabetes, lipid disorders, cancers and overall debility are 
discussed. 
Harding et al14 systematically reviewed the evidence base for the effectiveness of palliative care in 
PLWHIV from 1981 to 2003. Most data was generated in high income countries and in the pre-
HAART era.  It was clear that palliative care was effective in the management of pain, symptoms and 
anxiety and improved insight and spiritual well-being. Home palliative care and inpatient hospice 
care significantly improved patient outcomes. However, there was a lack of standardised 
experimental methods and a dearth of studies done in low-income/ sub-Saharan countries. 
ii)  Studies in sub-Saharan Africa: 
To evaluate outcomes of integrated palliative care within HIV outpatient settings, Harding et al75 
compare patient outcomes at 2 clinics in Tanzania, which had similar patient populations and ART 
treatment and care programmes. Before the study was started, a multidisciplinary palliative care 
team was formed at one clinic (the intervention site). All HIV clinical staff at that clinic received a 
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minimum of one week with an ongoing training program in place. A supply of essential palliative 
care drugs, including morphine, was put in place, which was not the norm for the comparison site, 
where also no training took place. 
At both clinics patients were recruited that had clinically significant pain or symptoms as assessed by 
the APCA African palliative outcome scale (POS) - the only symptom assessment tool validated in 
Africa76- which assesses prevalence of physical, psychological, emotional and spiritual problems in 
patients and their families and is adapted for a range of literacy skills. The medical Outcome Study-
HIV (MOS-HIV) was used to measure quality of life. Sample size calculations were based on the APCA 
African POS pain score. Patients were followed fortnightly until week ten using the 2 self-report 
outcome tools. At the onset of the study the intervention site had better POS, physical health and 
mental health scores than the comparison site, as the palliative care clinical skills had been 
introduced before the study was started. All scores improved significantly more over time at the 
intervention site, and this improvement was not associated with CD4 count or ART. Even though the 
study is not randomised and the results may be overinflated, the study proves without doubt that 
simple palliative care training, support and drug availability in addition to standard HIV care 
improves the quality of HIV outpatients. 
The protocol for a phase III randomised control trial with qualitative component was presented by 
Lowther et al77. The TOPCare (Treatment outcomes in palliative care) study was designed to assess 
the effectiveness of nurse-led palliative care interventions for patients on ART at 2 outpatient clinics, 
one in Mombasa, Kenya, and the other in Cape Town, South Africa. The intention is to provide 
scientifically sound evidence of this effectiveness and to aid in informing policy makers of the 
importance of including palliative care in general HIV care.  
 
Summary of literature review 
Many international studies as well those done in southern Africa highlighted high symptom 
prevalence, physical and psychological, and burden amongst PLWHIV in the pre- HAART as well as 
the current treatment era. Being on HAART did not change symptom burden and symptom indices 
worsened with increasing treatment time. 
Pain is very common, under-reported, poorly recognised and inadequately treated. Poor pain and 
symptom control in general results in poor quality of life, poor treatment adherence and suicidal 
ideation. Impact of side effects, symptoms, and both were associated with impaired physical and 
social functioning. 
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A strong case is made to use pain/symptom assessment tools in clinical practice to improve 
symptom recognition and management as well as to explore barriers to adequate pain management. 
Patient related barriers to symptom control include concern about side effects, fear of addiction, 
interpreting symptoms as disease progression, accepting suboptimal care, fatalism and fear of 
distracting the physician from treating the disease. Barriers assigned to clinicians were lack of 
adherence to protocols, lack of knowledge of pain management, inadequate communication, fear of 
analgesia misuse/abuse and reluctance to address end-of-life issues. Curative focus, lack of access to 
specialist pain management, stigma and discrimination were service factors in need of improving. 
It is made clear that palliative care interventions are an important part of routine care of all HIV 
infected persons. Palliative care was effective in the management of pain, symptoms and anxiety 
and improved insight and spiritual well-being. Minimal basic palliative care training of the clinic staff 
providing standard HIV care, continuing support of staff and palliative care drug availability 
improved the quality of life of patients attending HAART clinics in southern Africa significantly. 
 
 
 
Rationale for the study 
No studies could be found that assessed the symptom prevalence, burden or efficacy of 
management in PLWHIV in Namibia. This study serves to add to the knowledge of symptom 
prevalence and burden of HIV/AIDS in underdeveloped and under-researched countries. Of the 
available data collection tools the Memorial Symptom Assessment Scale (MSAS) was chosen as it has 
been used in many studies, including sub-Saharan Africa11,51 to assess prevalence and burden of 
multiple symptoms in patients with cancer, AIDS or advanced medical illnesses51. The short form 
(MSAS-SF)78,38 is easy to use, is not time-consuming and has useful subscale indices to calculate 
distress. 
The outcome of an investigation into Health care providers’ perceptions regarding symptom 
prevalence and assessment might assist in creating awareness of the suffering of PLWHIV as well as 
improved symptom assessment and management. 
 
 
30 
 
AIM 
The aim of this study is to assess the prevalence and associated burden of symptoms in patients 
attending an HIV clinic in Swakopmund and local general practitioners’ awareness of the symptom 
burden and assessment in HIV patients. 
 
OBJECTIVES: 
1) Assessment of symptom prevalence and severity  in HIV patients attending a HAART clinic at 
the Swakopmund State Hospital  
2) Investigation of symptom reporting by HIV patients on HAART during follow-up visits 
3) Evaluation of local health care providers’ perceptions regarding symptom prevalence and 
burden and the importance of symptom assessment in HIV patients receiving HAART. 
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METHODOLOGY 
 The study was conducted in 2 parts: 
3) Assessment of symptom prevalence and severity in HIV patients on HAART attending the 
HIV clinic at the Swakopmund State Hospital  
4) The evaluation of general practitioners’ perception regarding the symptom burden and 
importance of symptom assessment in HIV patients receiving HAART 
Study design and study site 
 This was a cross-sectional descriptive study conducted at the HIV clinic at the State Hospital in 
Swakopmund, Namibia, and amongst general practitioners working in the Erongo region. 
Study population 
1) HIV patients: 
The study population consisted of HIV patients on HAART attending the dedicated HIV clinic 
of the Swakopmund State hospital. The latter provides HAART to 3000 patients living in and 
around Swakopmund and which are not privately insured. 
 
2) General practitioners: 
Swakopmund is part of the Erongo region of Namibia. Non-specialist doctors providing HIV 
care working in the public and the private health sector formed the study population for the 
second part of the study. 
Inclusion and exclusion criteria 
1) HIV patients:  
Patients 18 years and older on HAART attending the HIV clinic on study days and consenting 
to study participation were included in the study.  
 
2) General practitioners: 
All medical officers working at the State Hospitals and private practitioners practising in the 
Erongo region were invited to take part in the study. Specialists were excluded from the 
study because no specialists are employed in the public sector of the Erongo region and 
none of the private specialists in the region are actively involved in providing HAART. 
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 Sample size 
1) HIV patients 
 
A minimum sample size of 96 was calculated before data collection according to the 
following formula: 
  =
 (1 −  )  
  
 
  where  n= sample size 
  p=anticipated patient proportion 
  d= precision on either side of the proportion 
  z=1.96, when calculating with a confidence interval of 95%.  
Previous studies using the MSAS-SF have shown a median symptom prevalence ranging from 
4 to 10 of 32 queried. The pain prevalence of about 50% in several studies was used for the 
anticipated population proportion (p= 0.5) being symptomatic, allowing for a range from 
40% to 60% (d= 0.1). 
2) General practitioners 
All 35 general practitioners and medical officers working in the Erongo region had available 
email addresses and were invited to take part in the study. 
Sampling 
HIV patients 
Simple random sampling took place on study days by inviting every fifth patient that came to the 
clinic for follow-up treatment to participate. If a patient declined, the patient next in line was 
invited. 
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Data collection 
 Data collection tools: 
1) HIV patients: 
i) The Memorial Symptom Assessment Scale- Short Form (MSAS-SF) (Appendix 1) 
The MSAS-SF was used to measure the prevalence and associated burden of symptoms over a 7 day 
period. It is a validated patient-rated data collection tool, the short form of which rates the severity, 
frequency and distress associated with 32 prevalent physical and psychological symptoms over a 7 
day period 78,38.  The distress caused by the physical and psychological symptoms are rated on a 5-
point (0-4) Likert scale. Zero is assigned to symptoms that are not present. 
 Separate subscales can be calculated 38,33: 
1.  Global symptom distress index (GDI):  an average of the symptom scores for 4 psychological 
symptoms (feeling sad, worrying, feeling irritable, feeling nervous) and 6 physical symptoms 
(pain, lack of energy, lack of appetite, feeling drowsy, constipation, dry mouth) 
2. Physical symptom distress score (PHYS): an average of 12 prevalent physical symptom scores 
(pain, lack of energy, lack of appetite, feeling drowsy, constipation, dry mouth, nausea, 
vomiting, change in taste, weight loss, feeling bloated, dizziness) 
3. Psychological symptom distress score (PSYCH): an average of 6 prevalent psychological 
symptoms scores (feeling sad, worrying, feeling irritable, feeling nervous, difficulty sleeping, 
difficulty concentrating) 
4. Total MSAS score (TMSAS): an average of the symptom scores of all 32 symptoms 
The potential range of these scales is from zero (minimal distress) to four (maximal distress)33, and a  
score greater than one implies the presence of significant distress38. 
The subscales PHYS, GDI and TMSAS have been correlated with extend of a disease, but GDI, PHYS, 
PSYCH and the total number of symptoms can also be correlated to quality of life51,79. 
 
ii) Data extraction tool (Appendix 2) 
A data collection form (Appendix 2), which was based on data collection tools used in similar 
studies43,53,  was drawn up to collect the following data from the patients’ clinic cards (a patient 
record that accompanies the patients): 
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Demographic data: age, sex, employment status, CD4 count, viral load, years on treatment, HAART 
regime; these were chosen to determine whether there is a relationship between the data and the 
symptoms reported in the MSAS. 
Symptom reporting: any symptoms that the study participant complained of during the previous 4 
months of clinic visits as well as on the study day were recorded, together with the treatment 
received. 
Pilot study of data collection tools: 
The clinic staff members (nursing sisters and voluntary HIV counsellors) were used to pilot the data 
collection procedure and the questionnaire for clarity and coherence. A registered nursing sister 
working at the HIV clinic was initially assigned to help with administering the MSAS-SF and filling in 
the demographic data. During a small pilot study with 10 patients (not included in the results) it 
became clear, that the familiarity of the patients with the clinic sister deterred them from answering 
the questions truthfully. A retired nursing sister was then employed to help with the study. 
2) General practitioners 
 
iii) General practitioner Questionnaire (Appendix 3): 
The original aim was to assess general practitioners’ symptom recognition and appropriateness of 
treatment based on the outcome of the symptom assessment of the study population above. It 
turned out, however, that hardly any symptoms were reported in the clinic cards despite quite a few 
being reported in the MSAS questionnaire. Instead, after discussion with the supervisor, a 
questionnaire was designed as a preliminary investigation to assess the awareness of general 
practitioners of the burden of disease in patients living with HIV and their opinions on the need for 
proper assessment and treatment of symptoms in conjunction with treatment of HIV with HAART 
treatment. The design was an attempt to find some answers to why symptom assessment was 
virtually non-existent and what influence general practitioners’ views could have on the big 
discrepancy between true symptom report and MSAS questionnaire reporting. Two retired general 
practitioners were used for a pilot study to test the questionnaire for comprehensibility. 
 
 
 
35 
 
 Data collection procedure: 
 
1) HIV patients 
The clinic staff members (nursing sisters and voluntary HIV counsellors) were briefed about the 
study and regarding confidentiality.  A retired nursing sister was employed to help with the study. 
She was trained in research ethics and the study protocol. 
The information sheet (appendix 4), the questionnaire (appendix 1) and the consent form (appendix 
5) were translated into Afrikaans, Oshivambo, Oshiherero, and Khoekhoegowab by forward and 
backward translation and were administered in the language of choice of the study participant. 
Information sheets were left in the clinic waiting room for patients to browse through at their own 
leisure. Eligible patients were approached by the HIV counsellors to take part in the study when they 
reported for their follow-up visits.  Interviews were held in a separate room at the HIV clinic. The 
study was then explained by the research nurse in line with the information sheet (appendix 4). She 
then checked the understanding of the patient and gave an opportunity to ask questions. The fact 
that participation in the study and consent were voluntary was reiterated. Assurance was given that 
they could withdraw at any stage without influencing their care and that all data would be treated 
strictly confidential before consent was signed by the patient.  
The short form of the Memorial Symptom Assessment Scale (MSAS-SF) (appendix 1) was then 
administered. Because literacy could not be assumed in the study population, the research nurse 
read out the questions while participants could also read the questionnaire and entered the 
responses. Only in Oshivambo speaking patients who could not read or speak one of the other 
languages, an HIV counsellor read out the questions and translated the responses. Even though the 
study participants were given the choice of their own language most patients wanted to 
communicate in English or Afrikaans. 
 Patients in Namibia making use of the public health system all carry their clinic cards with them. 
These are supposed to contain all the records of clinic visits, including patients’ complaints, blood 
results and medications prescribed. In addition HIV clinics keep separate folders containing data 
specific to the HIV management of the patients. The consent form included a request to have access 
to that information during the interview. Data extracted by the research nurse were the 
demographic data, most recent CD4 count and viral load, records of symptoms reported by the 
patient during the clinic visits on the study day and in the preceding 6 months, as well as measures 
taken by the health care professionals to address the symptoms (appendix 2). 
36 
 
 
2) General Practitioners 
 The questionnaire  and an accompanying letter (appendix 3) that explained the essence of the study 
was sent by email to all general practitioners treating HIV patients in private and public health 
services in the Erongo region, Namibia, with the request to fill out the questionnaire and to return it 
to the sender. A list of names and addresses were obtained from the local independent practitioners 
association and the Erongo regional office respectively. Two follow-up reminder mails were sent to 
improve the response rates. 
 Data storage and Confidentiality 
1) HIV patients 
The consent forms containing the patients’ names and study numbers and the questionnaires 
containing the study number only were stored separately. The questionnaires are stored separately 
from the consent forms in a locked filing cabinet in the researcher’s office for future reference. The 
study computer is password protected.  
2) General Practitioners 
The completed questionnaires were printed out and numbered. After extracting the data they were 
stored in the same filing cabinet as the questionnaires above. 
 
 Data analysis: 
1) HIV Patients: 
The data was entered into a purpose designed Excel spreadsheet, and subsequently imported into 
SSPSS for analysis. Descriptive data were generated for the patient characteristics and MSAS-SF 
scores. Prevalence and associated burden for each item and the subscale scores of global, physical 
and psychological scores were calculated. 
The latter 4 scores were used as dependent variables in a univariate analysis to test the association 
with the following independent variables: age (continuous), employment (two levels of yes/no), CD4 
count (2 levels of <=350/>350), gender (two levels of female/male) and months on treatment 
(continuous). 
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2) General Practitioners: 
Data were entered into an Excel spreadsheet and then analysed using IBM SPSS Statistics for 
windows. 
 
Ethical considerations 
Ethical approval 
Ethical approval for the research was requested and obtained from the Human Research Ethics 
Committee of the University of Cape Town (appendix 6) as well as from the Ethical Committee of the 
Ministry of Health, Namibia (appendix 7) before requesting and receiving permission from the 
Erongo regional office and the principal medical officer of the Swakopmund hospital to use their 
facility for the research (appendix 8). 
Protection of vulnerable population 
“Vulnerable persons are those who are relatively (or absolutely) incapable of protecting their own 
interests. More formally, they may have insufficient power, intelligence, education, resources, 
strength or other attributes to protect their own interests”80  
HIV patients attending state clinics are a particularly vulnerable group of people. Not only does the 
stigma attached to HIV make patients fear lack of confidentiality; poverty, language barriers, lack of 
education, limited health facilities and lack of knowledge regarding scientific western medicine make 
this group of people extremely vulnerable to exploitation 81. 
The information sheet (appendix 5) given to the patients to read and to take home contains most 
measures taken to protect the study population as well as the ethical considerations regarding the 
study: 
 Information given to the participants before they sign consent should be given in a 
culturally appropriate way and in the local language 82. The information sheet, 
questionnaire and consent form were translated into Afrikaans, Oshivambo, Oshiherero and 
Khoekhoegowab and the content of the information sheet discussed in the study 
participant’s language. 
 Voluntary participation in the study as well as the right to withdraw trial without reprisal 
and without having to give a reason was reiterated 
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 The community should receive fair benefits from the study, be it financial or in the form of 
education, improved health services or employment81. Even though there will be no direct 
benefits for the participants, the results of the study will be displayed in the form of a 
poster at the clinic. It might encourage better doctor-patient communication with resultant 
better symptom control. 
 Contact numbers were provided to the study participants in case of problems or questions 
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RESULTS 
Part 1: HIV patients 
Sample characteristics 
During the four week data collection period 110 participants were enrolled in the study. Three 
female patients withdrew consent after completing the questionnaire because they wanted to 
discuss participation with their partners first. Although arrangements were made for a renewed 
discussion, they did not return. One participant, known with bipolar mood disorder, was excluded 
because she was psychotic at the time. She was referred to the clinic medical officer for 
management. In two cases the symptom data were incomplete. 
The clinical and demographic characteristics of the 104 participants included in the final sample are 
presented in Figure 1. 
The mean age of the sample was 39 years (SD=9 years; minimum=19, maximum =60). The majority 
(61.5%) of the participants were females. The overall employment status was 66.2%; 80% of the 
males and 57.8% of the females were employed. 
Figure 1: Demographic and Clinical Characteristics of the Sample 
 Minimum Percentile 
25 
Median Percentile 
75 
Maximum Mean Standard 
Deviation 
Age 19 33 40 45 60 39 9 
CD4 82 281 417 544 1566 444 230 
Months 
on Rx 
1 16 40 75 162 48 35 
 
 Count % N=104 
  Female 64 61.5 
Male 40 38.5 
Employed No 35 33.7 
Yes 69 66.3 
CD4 <350 40 38.5 
>=350 64 61.5 
    
gender * Employed Crosstabulation 
 Employed Total 
No Yes 
Gender Female Count 27 37 64 
% within gender 42.2% 57.8% 100.0% 
% within Employed 77.1% 53.6% 61.5% 
Male Count 8 32 40 
% within gender 20.0% 80.0% 100.0% 
% within Employed 22.9% 46.4% 38.5% 
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The average time on HAART was 3-4 years (median 40 months; mean 48 months; minimum 1, 
maximum 162).  
Eight different treatment regimes were found amongst the participants (Table1). Despite the 
availability of the fixed dose combination regime Tenofovir (TDF)/Emtrictabine (FTC)/Efavirenz (EFV), 
not even participants recently started on ART received it. The most commonly prescribed 
combination was Tenofovir (TDF), Lamivudine (3TC) and Nevirapine (NVP); 3 patients even still 
received Stavudine (D4T). 
Table 1: HAART regimes 
Treatment regime Valid  N 
 AZT/3TC/EFV 8 
AZT/3TC/NVP 23 
D4T/3TC/EFV 1 
D4T/3TC/NVP 2 
TDF/3TC/AZT/LVP-r 3 
TDF/3TC/EFV 24 
TDF/3TC/NVP 42 
TDF/D4T/NVP 1 
Total 104 
AZT=Zidovudine;; 3TC=Lamivudine; D4T=Stavudine; TDF=Tenofovir; LVP-r=Ritonavir boosted Lopinavir; NVP=Nevirapine; EFV=Efavirenz 
 
The latest mean CD4 count was 444 (median 417; SD 230, minimum= 82, maximum =1566). 38.5% 
had a CD4 count of less than 350, which was the cut-off value at the time for starting HAART.  
Although regular viral load testing had been introduced at the clinics shortly before data collection, 
not enough participants had recent values available for inclusion in the study. Only 32 viral loads 
were available. Although all of those study participants had been on treatment for more than a year, 
only four had a viral load less than or equal to 20. Of the five patients that had a viral load above 
1000, only one was receiving second line treatment. 
 
Symptom Prevalence and Distress 
The mean number of symptoms was 5.99 (median 5, SD 4.912, minimum=0, maximum=20) (Table 2).  
A third of participants had 8 symptoms or more. Only ten patients (9.6%) were symptom free. 
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Table 2: Symptom prevalence and statistics 
Nr of 
symptoms 
Frequency Percent Cumulative 
percent 
0 10 9.6 9.6 
1 11 10.6 20.2 
2 9 8.7 28.8 
3 8 7.7 36.5 
4 9 8.7 45.2 
5 12 11.5 56.7 
6 7 6.7 63.5 
7 6 5.8 69.2 
8 6 5.8 75.0 
9 3 2.9 77.9 
10 3 2.9 80.8 
11 3 2.9 83.7 
13 6 5.8 89.4 
14 4 3.8 93.3 
15 3 2.9 96.2 
16 1 1.0 97.1 
17 1 1.0 98.1 
20 2 1.9 100.0 
Total 104 100.0  
 
Symptom prevalence statistics 
Total 
Symptoms 
Mean 5.99 
Median 5.00 
Variance 24.126 
Std. Deviation 4.912 
Minimum 0 
Maximum 20 
Range 20 
 
The most common physical symptoms were pain, cough, difficulty concentrating, difficulty sleeping, 
lack of energy, numbness /tingling in hands and feet, feeling bloated, dry mouth, problems with 
sexual interest and itching. There were 44 (42.3%) participants who reported pain which caused 
almost half of those to suffer from high levels of distress. Sweating, although not amongst the most 
frequently occurring symptoms, scored high on the distress scale (Table 3, 4). 
 
Psychological symptoms were reported more frequently than physical ones and caused high levels of 
distress when present (Table 3, 4). All symptoms used to calculate the psychological distress score 
(PSYCH) are amongst the 10 most commonly occurring symptoms overall: worrying, feeling sad, 
pain, feeling irritable, feeling nervous, cough, difficulty concentrating , difficulty sleeping, lack of 
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energy and numbness/tingling in hands and feet. Feeling nervous was the only one of the 
psychological symptoms that did not fall amongst the highest scoring high distress symptoms 
 
Table 3: Symptom frequency 
Physical symptom Occurrence 
total (N) 
percent High distress 
(N)* 
Percent  with high 
distress** 
MSAS score/ high 
distress*** 
Pain 44 42.3 21 47.7 79.2 
Cough 30 28.8 7 23.3 28 
Difficulty 
Concentrating 
27 26.0 8 29.6 30.4 
Difficulty Sleeping 25 24.0 11 44.0 41.6 
Lack of Energy 25 24.0 8 32.0 30.4 
Numbness/ 
Tingling 
25 24.0 5 20.2 20 
Feeling Bloated 23 22.1 6 26.0 20.8 
Dry Mouth 22 21.1 5 22.7 18.4 
Problems with 
Sexual Interest 
20 19.2 4 20.0 16 
Itching 20 19.2 7 35.0 26.4 
Sweats 19 18.3 8 42.1 31.2 
Psychological 
symptom 
     
Worrying 51 49.0 21 41.2 71 
feeling sad 45 43.3 15 33.3 50 
Feeling irritable 43 41.3 9 20.9 30 
Feeling nervous 33 31.7 7 21.2 23 
*quite a bit and very much/ frequently and almost constantly 
**percentage of those reporting the symptom 
***sum of high distress scores 3.2+4 or 3+4 
 
. 
 
Table 4: Most common symptoms 
 According to occurrence According to high distress According to MSAS score 
1 worrying pain Pain` 
2 Feeling sad worrying worrying 
3 Pain Feeling sad Feeling sad 
4 Feeling irritable Difficulty sleeping Difficulty sleeping 
5 Feeling nervous Feeling irritable Sweats 
6 Cough Difficulty concentrating Difficulty concentrating 
7 Difficulty concentrating Lack of energy Lack of energy 
8 Difficulty sleeping sweats Feeling irritable 
9 Lack of energy Cough Cough 
10 Numbness/ tingling itching Itching 
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The MSAS scores give an indication of the level of symptom distress and of quality of life. Even 
though the average scores are all less than 1 (Figure 2), indicating minimal distress, there were 
participants with very high distress scores, psychological distress being the highest.  A quarter of the 
participants had a global distress index equal to or above 1; high psychological distress was found 
amongst 40 of the participants. 
Figure 2: MSAS scores 
 Valid N Minimum Maximum Mean Standard 
Deviation 
Median Percentile 
25 
Percentile 
75 
TMSAS 104 .00 1.88 .42 .40 .32 .15 .59 
GDI 104 .00 2.94 .67 .66 .56 .13 .97 
PHYS 104 .00 1.93 .39 .45 .27 .00 .57 
PSYCH 104 .00 3.43 .80 .87 .47 .00 1.33 
 
Frequencies of significant distress (>=1 is significant) 
Variable >=1 <1 total 
TMSAS 10 94 104 
GDI 25 79 104 
PHYS 11 93 104 
PSYCH 40 64 104 
 
Associations with symptom burden indices 
For the variables employment status (yes/no), sex (female/male) and CD4 count (<350/>=350) the 
Mann-Whitney U test was used to test their associations with the MSAS-SF scores (Table 5). The 
continuous variables age and months on treatment were tested using the Spearman’s rho test (Table 
6).  
The association with type of HAART regime was not tested; the high number of different regimes 
amounts to very small sample sizes.  Most of the regimes prescribed are no longer part of the 
recommended first line regimes according to the new local guidelines. Median values of TMSAS, GDI 
and PSYCH were significantly different between employed/unemployed (Figure 3), between males 
and females (Figure 4) and PHYS significantly different between males and females. There was no 
association with the CD4 count (Figure 5). Time on treatment is not significantly related to any of 
TMSAS, GDI, PHYS or PSYCH scores, but younger age was related to higher GDI (Table 6). 
Box and whiskers plots in Figures 3 to 5 diagrammatically present the associations of employment 
status, gender, and CD4 count with the symptom indices. The bottom and the top of the boxes are 
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the first and third quartiles, while the band inside the box represents the median. The ends of the 
whiskers represent the lowest value still within 1.5*IQR (interquartile range) of the lower quartile, 
and the highest value still within 1.5*IQR of the upper quartile. Any data not included between the 
whiskers is plotted as an outlier with a numbered small circle, the number representing the number 
of the study participant. 
Figure 3: Association of employment status with symptom indices 
 Employed 
Valid 
N 
Minimum Maximum Mean Standard 
Deviation 
Median Percentile 
25 
Percentile 
75 
TMSAS 
 
No 35 .00 1.88 .53 .46 .35 .22 .70 
Yes 69 .00 1.74 .37 .37 .26 .05 .51 
GDI 
 
No 35 .00 2.80 .86 .72 .72 .32 1.06 
Yes 69 .00 2.94 .58 .62 .36 .00 .92 
PHYS 
 
No 35 .00 1.93 .46 .46 .27 .13 .67 
Yes 69 .00 1.73 .36 .44 .27 .00 .53 
PSYCH No 35 .00 3.43 1.09 1.03 .83 .27 1.60 
Yes 69 .00 2.50 .66 .74 .33 .00 1.27 
 
  Box and Whiskers Plot for employment status                       
    
   
 
TSMAS, GDI and PSYCH are significantly increased in the unemployed 
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Figure 4: Association of gender with symptom indices 
 
 
Box and Whiskers Plot for gender 
 
 
All 4 MSAS scores are significantly higher in female patients 
 
 
 
 
 
 
 Gender 
Valid 
N 
Minimum Maximum Mean Standard 
Deviation 
Median Percentile 
25 
Percentile 
75 
 
TMSAS 
 
GDI 
 
PHYS 
 
PSYCH 
Female 64 .00 1.88 .51 .45 .39 .17 .70 
Male 40 .00 1.16 .28 .26 .20 .05 .42 
Female 64 .00 2.94 .81 .72 .66 .18 1.23 
Male 40 .00 1.70 .46 .50 .24 .00 .84 
Female 64 .00 1.93 .49 .50 .33 .13 .67 
Male 40 .00 1.20 .25 .30 .13 .00 .37 
Female 64 .00 3.43 .96 .96 .67 .17 1.57 
Male 40 .00 1.90 .56 .62 .30 .00 1.08 
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Figure 5: Association of CD4 count with symptom indices 
 CD4 
Valid 
N 
Minimum Maximum Mean Standard 
Deviation 
Median Percentile 
25 
Percentile 
75 
TMSAS <350 40 .00 1.77 .45 .45 .34 .15 .63 
>=350 64 .00 1.88 .40 .38 .31 .14 .56 
GDI <350 40 .00 2.94 .73 .73 .63 .00 1.01 
>=350 64 .00 2.80 .63 .62 .54 .16 .97 
PHYS <350 40 .00 1.73 .44 .48 .27 .00 .60 
>=350 64 .00 1.93 .36 .42 .27 .00 .57 
PSYCH <350 40 .00 3.43 .80 .92 .45 .00 1.27 
>=350 64 .00 3.33 .81 .84 .52 .00 1.38 
 
Box and Whiskers Plot for CD4 count 
 
There is no association between CD4 count and MSAS scores 
 
Table 5: Null Hypotheses for the associations of MSAS scores with gender, employment status and CD4 count 
Variable By Test Statistic p Conclusion 
TMSAS 
Gender 
7.5 0.006 Reject H0 
GDI 6.393 0.011 Reject H0 
PHYS 7.367 0.007 Reject H0 
PSYCH 5.137 0.023 Reject H0 
TMSAS 
Employed 
4.098 0.043 Reject H0 
GDI 4.43 0.035 Reject H0 
PHYS 1.948 0.163 Do not reject H0 
PSYCH 4.799 0.028 Reject H0 
TMSAS 
CD4 
-0.13 0.896 Do not reject H0 
GDI -0.393 0.694 Do not reject H0 
PHYS -0.752 0.452 Do not reject H0 
PSYCH 0.464 0.643 Do not reject H0 
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Table 6: Associations of time on treatment and age with symptom indices 
 
Correlations  
 Age Months on 
Rx 
TMSAS GDI PHYS PSYCH 
Spearman's 
rho 
Months 
on Rx 
Correlation 
Coefficient 
 1.000 .038 .081 .003 .122 
Sig. (2-tailed)   .701 .857 .977 .219 
N  104 104 104 104 104 
age Correlation 
Coefficient 
1.000  -.131 -.200
*
 -.146 -.088 
Sig. (2-tailed)   .183 .042 .140 .376 
N 104  104 104 104 104 
**. Correlation is significant at the 0.01 level (2-tailed).  Younger Patients have a higher GDI 
 
 
 
 
 
Correlation between symptom reporting during follow-up and during the study 
 
Participants of the study reported between zero and twenty symptoms according to the MSAS-SF 
questionnaire (Table 2).  When collecting information from notes made in the patients’ clinic cards 
during follow-up visits dating back 3 months and including the study day visit, the maximum number 
of complaints noted was two.  Cough and pain were the most commonly reported symptoms during 
follow-up. Other recorded symptoms were pruritus, mouth sores, diarrhoea, loss of appetite, lack of 
energy and oedema.  For 10 of the 28 reported pain complaints no treatment was recorded.  
 
Paracetamol and Ibuprofen were the most commonly prescribed analgesics; one patient received 
Codeine and another Tramadol. None of the patients complaining of cough were known asthmatics 
or previously diagnosed with TB. Higher symptom burden as assessed by the MSAS-SF did not 
correlate with higher symptom reporting during clinic visits (Table 7). 
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Table 7: Total Symptoms (MSAS-SF) * Total Clinic Card Symptoms Cross tabulation 
 
                                               Count Total Clinic Card Symptoms Total 
0 1 2 
Total Symptoms 
MSAS-SF 
0 10 0 0 10 
1 10 1 0 11 
2 7 2 0 9 
3 7 1 0 8 
4 6 2 1 9 
5 10 1 1 12 
6 5 1 1 7 
7 3 2 1 6 
8 4 2 0 6 
9 2 0 1 3 
10 2 1 0 3 
11 1 2 0 3 
13 4 1 1 6 
14 2 2 0 4 
15 2 1 0 3 
16 0 1 0 1 
17 1 0 0 1 
20 0 1 1 2 
Total 76 21 7 104 
 
  Bar chart 1: Total Symptoms (MSAS-SF) * Total Clinic Card Symptoms 
 
 
 
 
 
 
 
 
49 
 
Part 2: General practitioners 
 
Sample characteristics 
 
Requests to participate were emailed to all of the 35 general practitioners working in the Erongo 
region, of which 25 responded; 15 from the private and 10 from the public sector. 
 
General practitioners’ opinions (Table 8) 
 
The majority (88%) of participants agreed that symptom assessment and treatment is important 
alongside treatment with HAART, 84% believed symptoms to be more common in patients with low 
CD4 count. Physical symptoms were thought to be more common (56%) and only 25% felt that 
symptoms, when present, caused little distress. Symptoms were not generally ascribed to treatment 
side effects and HAART was not expected to readily resolve symptoms and make symptomatic 
treatment unnecessary; almost half (44%), however, believed patients on HAART to be generally 
symptom free.  The majority (76%) believed that patients would voice their symptom complaints 
during routine follow-up. 
 
Table 8: General Practitioners’ opinions 
 
 Strongly 
disagree/disagree 
Agree/Strongly 
agree 
N % N % 
Patients on HAART are generally symptom free 14 56 11 44 
Symptoms resolve readily on HAART and symptomatic treatment is 
unnecessary 
16 64 9 36 
Symptoms are more common in patients with low CD4 counts 4 16 21 84 
Physical symptoms are more common than psychological ones 11 44 14 56 
Symptoms are usually related to treatment side effects 19 76 6 24 
During routine follow-up patients will complain of  symptoms should 
they be present 
6 24 19 76 
If symptoms are present, they cause little distress 19 76 6 24 
It is important to assess and treat symptoms in conjunction with 
treatment of HIV with HAART 
3 12 22 88 
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Bar chart 2: General practitioners’ opinions: 
 
 
As clinicians in the public service see a lot more PLWHIV than private practitioners do, the 
assumption was made that their respective opinions would differ. In the current small sample, 
however, that did not seem to be the case (Table 9). 
 
 
Table 9: Public versus private practitioner opinions 
 Public (N=10) Private( N=25) 
Strongly 
disagree/ 
disagree 
Agree/ 
Strongly 
agree 
Strongly 
disagree/ 
disagree 
Agree/ 
Strongly 
agree 
Patients on HAART are generally symptom free 
 
8 2 6 9 
Symptoms resolve readily on HAART and 
symptomatic treatment is unnecessary 
8 2 8 7 
Symptoms are more common in patients with 
low CD4 counts 
1 9 3 12 
Physical symptoms are more common than 
psychological ones 
6 4 5 10 
Symptoms are usually related to treatment 
side effects 
7 3 12 3 
During routine follow-up patients will complain 
of  symptoms should they be present 
1 9 5 10 
If symptoms are present, they cause little 
distress 
9 1 10 5 
It is important to assess and treat symptoms in 
conjunction with treatment of HIV with HAART 
2 8 1 14 
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Table 10: Null hypotheses Public versus private practitioner opinions 
Variable Chi-
Squared 
d.f
. 
p Fisher's 
p 
Conclusion* 
Patients on HAART* are generally symptom free 3.896 1 .048 .099 Do not reject 
H0 
Symptoms resolve readily on HAART and symptomatic treatment is unnecessary 1.852 1 .174 .229 Do not reject 
H0 
Symptoms are more common in patients with low CD4 counts .446 1 .504 .626 Do not reject 
H0 
Physical symptoms are more common than psychological ones 1.732 1 .188 .241 Do not reject 
H0 
Symptoms are usually related to treatment side effects .329 1 .566 .653 Do not reject 
H0 
During routine follow-up patients will complain of  symptoms should they be 
present 
1.791 1 .181 .345 Do not reject 
H0 
If symptoms are present, they cause little distress 1.791 1 .181 .345 Do not reject 
H0 
It is important to assess and treat symptoms in conjunction with treatment of 
HIV with HAART 
1.010 1 .315 .543 Do not reject 
H0 
*no significant difference between public and private practitioners’ opinions 
In this chapter the symptom prevalence and burden of the study population was presented, as well 
as the health professionals’ awareness of the plight of these patients. In the following discussion 
these results will be discussed in the context of the introduction and the literature review above. 
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Discussion 
In this chapter the results are discussed following the headings used in the literature review; 
symptom prevalence and burden, effect of treatment, under-reporting and under-assessment of 
symptoms, barriers to symptom management and the need for palliative care will be discussed. 
This was the first study to assess symptom experiences of patients living with HIV/AIDS in Namibia. 
The sample reflects the demographics of HIV infected patients accessing care in Namibia, being of a 
younger age group (average 39 years) and largely female (62%). In a recent review on the problem of 
pain in PLWHIV it was found that low-income countries and females were under-represented in the 
studies48. This study adds to the knowledge about the burden of symptoms in female and male 
patients living with HIV in developing countries. 
Palliative care includes but goes beyond the medical management of HIV/AIDS. According to the 
WHO definition it improves the quality of life of patients and their families facing the problems associated 
with life-threatening illness, “through the prevention and relief of suffering by means of early identification 
and impeccable assessment and treatment of pain and other problems, physical, psychosomatic and 
spiritual”
17. Equally, quality of life not only depends on good clinical care, but involves non-health 
related issues such as addressing poverty, stigma, gender equity, nutrition, sanitation, and housing 
and clean water supply. Symptom management is only a part of holistic patient care. This study on 
prevalence of symptoms emphasises the need for comprehensively addressing symptoms and 
suffering throughout the continuum of HIV disease as a first step towards holistic patient care. 
 
Symptom prevalence and burden 
Despite apparently normal functioning, patients coming for routine follow-up treatment were found 
to have a high 7 day symptom prevalence in the current study population on HAART; an average of 6 
out of possible 32 symptoms were reported. In the pre-HAART era Breitbart et al10,34 described that 
the presence of pain was associated with the number of concurrent symptoms, and in this study the 
average of symptoms present was 9 in those study participants who reported pain. 
As in many other studies43,53 psychological symptoms as well as pain are highly prevalent and cause 
for  distress. Pain decreases quality of life; it is associated with increased psychiatric disease43,26; it is 
associated with sleep disturbance and fatigue36,63. These associations alone may explain the 
presence of the ten most commonly reported symptoms in this study, excluding peripheral 
neuropathy and cough: the psychological symptoms (worry, feeling sad, irritable and nervous) as 
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well as pain, difficulty in concentrating and sleeping and lack of energy. So by properly assessing and 
managing pain, symptom burden can be reduced and quality of life improved. 
Harding and Sherr49 reported that symptom burden does not only influence quality of life, it also is 
associated with poor treatment adherence, treatment switching, sexual risk taking and viral 
rebound. High symptom burden that remains unaddressed might lead to self-care strategies that are 
harmful or ineffective63. Patients tire of side effects of treatment which might lead to non-
compliance16.  This is why the Namibian HIV treatment guidelines31 should emphasise symptom 
assessment and management much more clearly than only advising to be on the look-out for 
medication side effects, opportunistic infections and disease progression. Other than peripheral 
neuropathy and cough none of the common symptoms are obviously disease or treatment related, 
but they are still intricately linked to disease management. 
 Cough and pain were reported most common physical symptoms reported in this study.  Despite 
cough being reported in combination with sweats and/or chest pain, there was no indication in the 
clinic cards that these patients were investigated for TB. This constitutes missed opportunities to 
diagnose TB and to prevent the increased morbidity associated with late diagnoses and possible 
drug resistance. 
Women and unemployed patients had significantly higher distress as measured by the MSAS-SF 
subscales TMSAS, PSYCH and GDI. Females also suffered higher physical symptom distress, whereas 
younger patients had significantly higher global distress indices. More than half of the women 
participants were under the average age of the study population. Women also comprised most of 
the unemployed. The higher distress in the younger patients, the unemployed and in females is thus 
interlinked. The higher global burden amongst the younger patients could also result from being 
more educated, more outspoken and less fatalistic with regards to their disease. Fatalism is one of 
the concerns addressed in the Barriers Questionnaire designed by Ward et al83 when investigating 
patient barriers to symptom reporting. This might be that less evident in young adults; especially 
young females, who not only have their own lives ahead of them but also have to think of their 
young children’s future. These young women might be less willing to accept symptoms that remind 
them of their chronic disease and will not resort to passive acceptance. However, poor coping skills 
and little emotional, psychological or spiritual support will lead to increased physical and 
psychological morbidity5.  Lack of energy, one of the symptoms making up the physical component 
of the GDI, was commonly reported high distress symptom and might also be felt more acutely in 
the younger population. 
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This study confirms the finding of many other studies10,63,84 that women experience a higher 
symptom burden and  have also been shown to risk non-adherence to treatment in order to avoid 
side effects62.  A study by Breitbart85 showed that women and poorly educated patients are more 
likely to receive inadequate pain control. If symptoms are not addressed and are interpreted as 
treatment side effects this might lead to inadequate disease control. Women constitute thus a very 
vulnerable population and increased attention is required toward relieving their plight. 
Although not investigated as part of this study, symptom burden may be expected to be higher in 
the rural and poorer areas of Namibia, where unemployment and poor education are a bigger 
problem than in urban areas. Mothers often stay alone with their children in the rural homes and 
the chronically ill usually migrate back to these homes. Distances to the nearest clinic and to any 
pharmacy for self-medication are greater.  
 Breitbart el al10 were the first to use the MSAS-SF to measure symptom prevalence and burden in 
AIDS patients. In their study the internal consistency of the subscales of the MSAS-SF was as high in 
that AIDS population as it was in cancer populations33. Since the advent of HAART symptom 
prevalence is still high, but the profile of prevalent symptoms that end stage cancer patients and 
AIDS patients had in common, has changed. Even though the MSAS-SF has been extensively used to 
collect data amongst patients with less advanced HIV disease on ART and in studies in sub-Saharan 
Africa, it has never been validated for these populations. High distress symptoms such as peripheral 
neuropathy, problems with sexual function/activity, body image, sleeping and concentration 
difficulties are not included in scales used to calculate global burden and physical distress. Different 
cultures might interpret and experience symptoms differently. In a study done in Uganda52 
additional distressing symptoms were identified, such as hunger and difficulties with 
moving/walking. The physical symptom distress score as well as the global symptom distress index 
might differ if these respective distressful symptoms were included in the calculations.  
The APCA-POS, which is a core outcome measure for palliative care in Africa, assesses physical and 
psychological symptoms, spiritual, practical and emotional concerns and psychosocial needs of the 
patient and family76. Despite it addressing palliative care needs to a much greater extent than the 
MSAS-SF, the latter was chosen for this study because of more detailed symptom assessment. The 
APCA-POS is used for clinical audits and for measuring outcomes of improvements made to existing 
palliative care. This study attempted to create an awareness of the symptom burden amongst 
PLWHIV.  Impeccable symptom control is a start towards improving patients’ quality of life and 
should be a routine part of patient care.  
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Irrespective of the above concern it has been shown without doubt internationally and locally that 
patients living with HIV have a high symptom burden, and that the issue at hand now is to improve 
symptom assessment and management50. 
Symptoms: Treatment or disease? 
Efavirenz/Emtrictabine (or Lamivudine)/Tenofovir is now the preferred regime in treatment naïve 
HIV patients internationally12 and locally as endorsed by the 2014 Namibian national guidelines31. It 
has been shown to achieve and maintain viral suppression whilst having a good tolerability profile. 
Symptoms such as peripheral neuropathy, nausea and vomiting, loss of appetite, abnormal taste of 
food, skin problems and abdominal discomfort were significantly less than with other HAART 
regimes12. Lamivudine (3TC) and Emitricabine (FTC) are pharmacologically similar and are clinically 
interchangeable86. 3TC has a shorter intracellular half-life than FTC, but it was shown that this did 
not lead to a significant increase in resistant HIV mutations87. However, only FTC is available in a 
fixed dose combination (FDC) with Tenofovir (TDF) and Efavirenz (EFV), which makes it the more 
favourable drug to use.  
It is a concern that despite national guidelines, the study participants were on 8 different treatment 
regimes; the most commonly prescribed HAART was TDF/3TC/NVP; only 20 % were on the 
recommended treatment regime. It is of concern that there are still patients receiving Stavudine, 
despite the recent 2014 guidelines31 strong recommendation to eliminate D4T based regimes. The 
previous 2010 Namibian national guidelines88 already warned against the well documented long-
term side effects, such as lipodystrophy, peripheral neuropathy and lactic acidosis. The guidelines 
also recommend that patients on AZT, NVP or D4T based regimes are identified and changed to the 
now available FDC formulation. Of the 76 study participants eligible for such a change provided they 
had sufficient viral suppression, only 29 had recent viral loads available; of these only 3 were 
sufficiently suppressed. 
This study confirms that even while well and on ART, PLWHIV experience many symptoms. This was 
also reported in an online survey amongst gay men living with HIV in the UK35, where the mean total 
number of symptoms was 14 for those on HAART and 10.3 for those not on ART. In the UK study 
psychological distress was the same for both groups, but PHYS scored higher in patients on HAART, 
although, as in the current study, the subscale scored less than one. HAART users had more pain, 
lack of energy, drowsiness and peripheral neuropathy; the latter two being known side effects of 
Efavirenz, Didanosine and Stavudine. The UK and the current Namibian study clearly showed that 
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HAART does not eliminate the symptom problem in PLWHIV, but optimal choice of treatment 
regimes can prevent unnecessary symptoms due to treatment side effects. 
Starting ART once the CD4 level is below 500 instead of the previous value of 350 was introduced 
locally in 2014. With an average CD4 count of 444 and 40% of study participants having a CD4 count 
of less than 350, the immune status is relatively low. Looking at these CD4 counts and corresponding 
treatment regimes, there seems to be a reluctance to change to second line treatment which could 
indicate that there are patients with undiagnosed treatment resistance which might lead to 
increased infectivity, morbidity and mortality. It is important that the recommended viral load 
measurements are adhered to and acted upon, in order to diagnose and treat insufficient viral 
suppression.  
 
 Under-recognition and under-reporting of symptoms/ barriers to symptom control 
There was a big discrepancy between the symptom prevalence as assessed by patient self-report by 
direct questioning using the MSAS-SF and the prevalence as reported in the clinic cards by the health 
care professionals during normal follow-up visits. The majority (90%) of patients reported at least 
one symptom in the questionnaire, the overall prevalence ranging from 0 to 22. Of these patients 
only 50 (48%) had symptoms recorded during follow-up visits, the maximum number of symptoms 
recorded being 2; although as discussed earlier the average number of symptoms identified by 
patients was 6. It is possible that the specific HAART records that are kept at the clinic have details 
that were not transferred to the clinic cards, but that alone would not explain the large disparity. It is 
clear that symptoms were not actively assessed. 
Patient-related barriers to reporting pain in cancer83 and AIDS patients41 could explain some of this 
disparity. Fear of distracting health care providers from treating the disease, interpreting symptoms 
as signs of disease progression, fear and concern about side effects and pill burden, inadequate 
communication72 as well as fatalism have been described as factors preventing patients from 
reporting symptoms41.  
During the pilot study it was clear that patients were reluctant to communicate symptoms to a 
familiar clinic sister. Despite using an unfamiliar research nurse in a separate room in the clinic for 
completing the questionnaires, the clinic as well as the community is small enough to know 
everybody else and watch their movement, so that some might have felt that privacy was not 
enough73. The symptom report during normal follow-up visits, as recorded in the clinic cards, in 
comparison to those reported in the questionnaire is also an indication of the reluctance to report 
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problems if not directly asked about symptoms. When designing the study the HIV clinics were not 
yet run by nurses and patients had a long wait until they got seen by the medical officers. That time 
was designated for filling in the questionnaire. When the data collection was started, the clinic had 
become a nurse-run clinic, waiting times were drastically improved and patients were reluctant to 
“waste time” and might not have taken the time to think about the questions and reported no 
symptoms in order to get home or back to work faster.  
 It is known that open ended questions are less sensitive in eliciting symptoms and that patients are 
more likely to recall symptoms when prompted with a list61.  A symptom check list that could be 
completed by the patient with or without the help of the health care provider would empower the 
patients to overcome a lot of the possible barriers to reporting symptoms and would assist health 
care providers with symptom assessment. 
Under-estimation and under-treatment of symptoms by health care providers is a well known 
fact39,40,65. Symptoms are often under-recognised either because health care providers do not ask, 
focus on the treatment of the disease only68 or consider them “subclinical”13. The health care 
providers in this study were all aware of the need for assessment and management of symptoms 
alongside HAART; most of them also knew that symptoms could be distressing and would not 
disappear readily by using HAART. However, 44% believed HIV patients to be generally symptom 
free. No other study could be found where it was made explicitly clear that health care providers 
assume that patients would report symptoms when present. Breitbart et al41,71 found that most 
clinicians, except for those with more knowledge regarding pain management, do not see patient 
under-reporting as a barrier to pain management. Increasing health professionals’ skills in symptom 
assessment and management as well as creating awareness about patients’ barriers to symptom 
reporting would improve patients’ quality of life. 
The majority of health care providers in this study associated high symptom prevalence with a low 
CD4 count. Even in the pre-HAART era, no association was found between CD4 count and symptom 
burden33. Fontaine et al 66 found that physicians’ recognition rates of symptoms were better in sicker 
patients, probably because they are expected to be symptomatic. 
Resnik et al68 showed that clinical assessment is more likely to focus on disease and markers of 
disease management than on patients’ personal experiences. Despite knowing that symptoms are 
not just due to medication side effect, there is little indication in this study that ANY symptoms were 
actively sought for. Other symptoms that were commonly reported in the MSAS-SF and could have 
been due to side effects or disease progression /opportunistic infections, such as peripheral 
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neuropathy, itching, bloatedness, dry mouth, sweats and drowsiness were not reported and hence 
not assessed for.  
 The advantages of nurse initiated HAART are faster and more available services, especially in rural 
areas where availability of doctors is limited. Nurses, however, are not medically trained in symptom 
control, diagnoses and management of other diseases. This might lead to under-recognition of 
symptoms and symptom aetiology, limited symptomatic control and late diagnoses of co-morbid 
conditions. Palliative care nurses are trained in symptom assessment and management and provide 
good total symptom control. The World Health Assembly resolution suggests that all health care 
providers should be trained in palliative care22. Integrating palliative care training into the nurse 
initiated HAART training would empower nurses to provide a better service, would benefit all 
patients attending HAART clinics in the country and would be a first practical step for the Namibian 
government to take to introduce palliative care into their health system. 
 The danger of identifying PLWHIV as asymptomatic is the failure to recognise a cluster of symptoms 
that when managed appropriately could improve quality of lives13 and treatment adherence. Wrong 
assumptions, such as “patients on HAART being symptom free”, “patients will report symptoms if 
present” and that “high CD4 counts protect from symptoms” lead to poor symptom assessment.  
Many practitioners had no formal training in HIV management or in palliative care. A strong case is 
made that such topics should be included in Continuous Medical Education programs and that 
stricter protocols are made available. Other studies38,15 also found provider recognition of symptoms 
poor and made a case for tools to be implemented to improve symptom recognition and 
management. 
Ward et al83 stressed the importance of good communication and addressing concerns in cancer 
patients before patients complain. The same should apply to PLWHIV. The importance of reporting 
symptoms and other problems should be part of every HAART initiation discussion. Many patients 
on HAART have presented initially with advanced AIDS and will have experienced dramatic 
improvements in well-being, which might make them tolerate symptoms rather than voice them. 
Patients should be informed that they will not be symptom free immediately when starting HAART,  
but that most symptoms can be treated effectively and it should be encouraged that non resolving 
symptoms need to be reported.  
Limitations of the study 
Being unused to taking part in research, the study participants might have benefitted from a second 
research assistant for informing them about the study and discussing questions and doubts before 
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the questionnaire was administered. Equally, the health practitioner recorded symptoms might have 
been a bit more, if the HIV clinic records were reviewed and not only the cards carried by the 
patients.  This would, however, not have influenced the conclusion, that symptom assessment by 
health care professionals and patient-reporting of symptoms is poor. 
Only general practitioners and state employed medical officers were requested to fill in the health 
professionals’ questionnaire. As the nurses now initiate the HAART and see patients for follow-up, 
they should have also been included. The data extracted from the clinic cards were mainly reported 
by nurses, so it is unlikely that their opinions differ a lot from those of the doctors as symptom 
assessment was poor, probably because the same incorrect assumptions were made. 
Palliative care  
Reported pain prevalence ranges from 50 to 67% throughout all stages of HIV disease48. In this study 
as in others43,53 psychological symptoms and pain rate high amongst symptoms causing a lot of 
distress. The concept of “Total Pain” applies17,86 in HIV medicine as is does for palliative care in 
general. PLWHIV as well as their families are confronted with many additional social and 
psychological problems besides the physical aspects of the disease89. Employment issues, finances, 
stigma, relationships and having to comply with care all influence the experience of pain. Kagee et 
al55 showed in a study done in South Africa that psychological distress was equally high in patients 
with other chronic diseases such as hypertension and diabetes. 
The approach to management of PLWHIV may be improved as in Tanzania75 which shows that 
minimal basic palliative care training of the clinic staff providing standard HIV care, continuing 
support of staff and palliative care drug availability improved the quality of life of patients attending 
these HAART clinics significantly. Similar training and assurance of drug availability would improve 
symptom assessment and management and should have the same effect amongst the local HIV 
population. A greater presence of motivated social workers at the relevant clinics might aid in 
alleviating some of the problems that are common especially amongst impoverished communities 
Even though medical officers working in the public health sector have a greater experience in 
treating HIV patients because of the greater number of patients, their perceptions and insights did 
not differ from general practitioners, who see fewer HIV patients, but theoretically have more time 
to spend exploring patient experiences. Private patients, who can choose their health care provider 
and can build up trust in a particular health care provider, might have fewer barriers to reporting 
symptoms. Good doctor-patient concordance regarding HIV treatment decision making and good 
communication results in better physical and psychological functioning32. Personalised treatment of 
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the disease and the total patient should be possible even in busy public hospital clinics. Even in the 
absence of a structured palliative care team or system, the assessment and treatment of pain and 
other distressing symptoms should be part of every doctor-patient interaction. Unaddressed physical 
and psychological symptoms have clinical implications as discussed above; leading to decreased 
treatment adherence and treatment failure with its consequences. 
The first decade of the HIV disease trajectory in the USA was characterised by high mortality and 
morbidity due to opportunistic infections. With the introduction of ART in the early nineties 
mortality declined drastically. In this current chronic disease era, which is managed by HAART, the 
decline in mortality has levelled off. Morbidity and mortality are increasing again due to accelerated 
of diabetes, lipid disorders, cancers, generalised debility and treatment failure4,90.  
In Namibia HAART only became available for all 10 years later than in the USA. Patients still present 
with opportunistic infections and very low CD4 counts. There are many risk factors to poor 
adherence and considering the natural progression of disease and its co-morbidities, it is likely that a 
time will come, when, as in the USA, mortality will be on the increase again.  
The 2014 World Health Assembly resolution on palliative care urges member states, of which 
Namibia is one, to integrate basic training and continuing education on palliative care “as a routine 
element of all undergraduate medical and nursing professional education, and as part of in-service 
training of caregivers at the primary care level, including health care workers, caregivers addressing 
patients’ spiritual needs and social workers”24. 
 As well as the benefits of providing palliative care focused on symptom management and 
psychosocial support,  end-of-life care for HIV patients still is and always will be a reality and it is a 
matter of urgency that steps are taken to provide palliative care to all HIV and other patients in 
Namibia. 
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Conclusion 
This study was the first in Namibia to investigate symptom prevalence and burden of HIV patients on 
HAART. It adds to the knowledge about the plight of HIV/AIDS patients in the less researched under 
developed countries. 
All objectives of the study were achieved: 
1) Symptom prevalence was high amongst the study population, psychological symptoms being 
by far the most common and distressing. In particular, young, unemployed, female patients 
reported high physical, psychological and global distress and special attention should be 
given to recognise the plight of this population group. 
2) Despite high symptom prevalence as measured by the MSAS-SF, patients are reluctant to 
report symptoms during follow-up visits. Patient barriers to symptom report need to be 
identified and addressed. 
3) Health care practitioners in the public and in the private health care sector agreed on the 
importance of good symptom assessment and management. However, quite a number 
assumed patients on HAART to be symptom free, that only a low CD4 count was associated 
with symptom burden and the majority assumed that patients would voice their symptoms.  
It is clear that, as in other countries, PLWHIV have a high symptom burden and that these symptoms 
are not managed appropriately, mainly because of poor symptom assessment. The fact that patients 
do not voice their problems and that health care providers assume that they will do so thus being 
seen as symptom-free is a recipe for misunderstanding, poor symptom assessment and lack of 
management. Palliative care training of all health care practitioners managing HIV patients needs to 
be introduced to help patients live well with their disease. 
 
 
Recommendations 
A number of recommendations can be made based on the above findings: 
1) Stricter adherence to treatment guidelines is recommended. 
i) Drugs, such as Stavudine, that are no longer recommended in standard treatment 
regimes should only be made available after special motivation by the prescriber.  
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ii) State pharmacy audits should be reviewed to see whether new treatment 
guidelines are adhered to. 
iii) In private practice the control boards of the medical aid schemes, which previously 
had HIV advisors, should reintroduce review of prescribed medicines before 
authorising payments. 
iv) Viral load monitoring should become a priority and systems need to be in place to 
ensure that failing treatment regimes are changed. 
 
2) A symptom check list should be made available to PLWHIV when presenting for follow-up. 
Symptom assessment can be improved by providing such a check lists to patients. Patients 
find it easier to recall symptoms when presented with a list59 and health care providers 
would be provided with a time saving list of symptoms to be addressed. 
 
3) To better assess symptom prevalence and burden in the African context, the MSAS should 
be revised and validated for PLWHIV, especially for those living in Africa. 
 
 
4) Symptom prevalence and burden is high in most patients with chronic illnesses55. It has been 
shown that even minimal palliative care training of nursing staff improves the quality of lives 
of PLWHIV75. Integrating palliative care training into nurse initiated HAART training, which 
could easily be extended to primary care nurses dealing with other chronic illnesses would 
be a start to providing palliative care in Namibia. 
 
5) Continuous Medical Education programs for general practitioners in public and private 
services should include education about symptom assessment and management in PLWHIV.  
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Appendices 
Appendix 1          Memorial Symptom Assessment Scale – Short Form (MSAS-SF) 
I) Instructions: Below is a list of symptoms. If you had the symptom DURING THE PAST WEEK, 
please check Yes. If you did have the symptom, please check the box that tells us how much the 
symptom DISTRESSED or BOTHERED you. 
 
 
 
 Check all the symptoms you have 
had during the PAST WEEK 
 
 
 
 
YES        
 
If YES: How much did it DISTRESS or BOTHER you? 
 
Not at 
All 
(0) 
A little 
Bit 
(1) 
Some-
what 
(2) 
Quite  
A Bit 
(3) 
Very 
Much 
(4) 
Difficulty concentrating       
Pain       
Lack of energy       
Cough       
Changes in skin       
Dry mouth       
Nausea       
Feeling drowsy       
Numbness/tingling in 
hands and feet 
      
Difficulty sleeping       
Feeling bloated       
Problems with urination       
Vomiting       
Shortness of breath       
Diarrhoea       
Sweats       
Mouth sores       
Problems with sexual 
interest or activity 
      
Itching       
Lack of appetite       
Dizziness       
Difficulty swallowing       
Change in the way food 
Tastes 
      
Weight loss       
Hair loss       
Constipation       
Swelling of arms or legs       
“I don’t look like myself”       
If you had any other symptoms 
experienced during the PAST 
week, please list them below 
and indicate how much the 
symptom distressed or bothered 
you 
1. 
      
2.       
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II) Below are other commonly listed symptoms. Please indicate if you had the symptom DURING 
THE PAST WEEK, and if so, how OFTEN it occurred 
Check all the symptoms you 
have had during the PAST 
WEEK 
Yes If YES, how often did it occur? 
Rarely 
(1) 
Occasionally 
(2) 
Frequentl
y 
(3) 
Almost constantly 
(4) 
Feeling sad      
Worrying      
Feeling irritable      
Feeling nervous      
 
Figure 1. Revised Memorial Symptom Assessment Scale Short Form 
38
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Appendix 2 
Demographic data 
 
Date     
Male/ Female     Age 
Employed:  Yes / No 
Last CD4 
Last Viral Load    Months on treatment 
HAART regime:  1) _____________ 
2) _____________ 
3) _____________ 
  
Other medication: 1) ____________________ 
2) ____________________ 
3) ____________________ 
Symptoms reported in clinic card:  Treatment received: 
1) ______________________________________________________________ 
2) ______________________________________________________________ 
3) ______________________________________________________________ 
4) ______________________________________________________________ 
5) ______________________________________________________________ 
6) ______________________________________________________________ 
7) ______________________________________________________________ 
8) _____________________________________________________________ 
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Appendix 3 
An investigation of the provision of holistic care to HIV patients in public and 
private health in Namibia 
 
Dear Colleague 
The above named study forms part of a requirement towards obtaining a Masters degree in 
palliative care. 
 Please assist me by taking the time to fill in the questionnaire below. There are no right or wrong 
answers. This is an attempt to compare health professionals’ perception of the presence of 
symptoms in HIV patients to the perceived symptoms of the patients themselves. 
Questionnaire: 
Please cross the appropriate box: 
 State Service:                     Private Practitioner:                        
 
 
 Strongly 
disagree 
1 
Disagree 
 
2 
Agree 
 
3 
Strongly 
agree 
4 
Patients on HAART* are generally symptom free 
 
    
Symptoms resolve readily on HAART and symptomatic 
treatment is unnecessary 
    
Symptoms are more common in patients with low 
CD4 counts 
    
Physical symptoms are more common than 
psychological ones 
    
Symptoms are usually related to treatment side 
effects 
    
During routine follow-up patients will complain of  
symptoms should they be present 
    
If symptoms are present, they cause little distress 
 
    
It is important to assess and treat symptoms in 
conjunction with treatment of HIV with HAART 
    
 
*HAART= highly active antiretroviral treatment 
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Appendix 4 
Information Sheet for: 
An investigation of the provision of holistic care to HIV patients in public and 
private health in Namibia 
Thank you for giving your time to hear about our study: 
What is the purpose of the study? 
Patients living with HIV have a lot of problems. We want to find out what health complaints people 
on HIV treatment have. We also want to find out whether they voice these complaints to their 
health care professionals and whether they are heard. 
Do I have to take part? 
Taking part is completely voluntary and you decision will NOT affect you care in ANY WAY. If you 
agree to take part you will be asked to sign a consent form to show that you wanted to take part. 
You can change your mind at any stage. 
What will happen when I take part? 
A researcher and a clinic nurse will ask you questions about the presence of pain or other symptoms 
you may have. At the same time we will investigate whether these complaints have been addressed 
by reading notes made in your clinic card. 
Benefits of the study 
There are no personal benefits to the study, but it might encourage you to voice your problems. The 
information you provide may help create awareness about what problems patients living with HIV 
do have. 
Disadvantage 
Although unlikely, some questions may make you feel sad or distressed. Should that happen, we will 
try and arrange time with a counsellor for you. 
Will my taking part in the study be kept confidential? 
All the information which we collect during the interview will be kept strictly confidential.  Your 
personal details (for example name and address) will be kept separately from the information you 
give. We will use a number and not your name on any information you give us. No-one outside the 
study will have access to the information you give us.  
For patients in this study we will record their illness. That information will be treated as 
confidentially as all the other information you give us, and no-one outside this study will be able to 
find out your name or any other information that would identify you.  
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How will I know about the results of the study? 
At the end of the study the results will be displayed on a poster at the clinic. 
 
Who is organizing the research? 
If you have any questions or need to talk to anyone about this research, you can contact the people 
listed below. Thank you for thinking about taking part in the study. 
 
If you have any questions about the study, contact: 
 
Dr Maja Brand, Swakopmund: Tel 429000 
 
If you have any questions about your human rights of any ethical issues about the study: 
UCT Research Ethics Committee:  
Mrs Lamees Emjedi: Telephone: 0027-21- 406 6338 
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Appendix 5 
Consent Form for 
An investigation of the provision of holistic care to HIV patients in public and 
private health in Namibia 
 
 
1. I confirm that I have read and understand the information sheet and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and I am free to withdraw at any time, 
without giving a reason, without my care being affected. 
 
 
3. I agree to take part in the above study. 
 
Name ________________________________    
 
Signature _____________________________  Date ________________ 
 
Researcher:  Signature __________________   Date: _______________   
   
Witness:  Name  
(from clinical team or family member) 
 
Signature ______________________________ Date: _______________ 
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Appendix  8   
Letter to local facility 
         Dr M. Brand  
         P.O. Box 2680 
         Swakopmund 
         Tel. 064-429000 
The Chief Medical Officer      29.4.2013 
Erongo District 
Private Bag 
Swakopmund 
 
Dear Dr Musasa 
An investigation of the provision of holistic care to HIV patients in private and public health in 
Namibia 
Following a discussion we had earlier, I am now writing to invite the HIV/HAART clinic of the 
Swakopmund hospital to join us as a study site in our research. 
The research is part of a Master’s thesis in palliative care. Palliative care is the care of patients with 
life threatening illnesses and focuses on relieving and preventing suffering and improving quality of 
life.  Patients living with HIV are known to have a high symptom burden and this study aims to assess 
that burden in the Swakopmund study population and to compare it to the awareness of healthcare 
professionals in Namibia and to the corresponding treatment provided. 
This study is a cross-sectional study to assess the prevalence of symptoms and the associated burden 
in patients using HAART. The Memorial Symptom Assessment Scale will be used. It is a patient rated 
instrument that has been used in many studies, including sub-Saharan Africa to assess prevalence 
and burden of multiple symptoms in patients with medical illnesses. 
The study received ethical approval from the Namibian ethical committee, ref. nr.:    , as well as the 
University of Cape Town Faculty of Health Sciences Human Research Ethics Committee, ref. nr:  . 
Your staff will be fully briefed about the study before commencing. 
Below an outline of some basic study information: 
 Who will be recruited? 
A total of 96 adult patients on HAART attending the HIV clinic on the agreed upon study days will be 
recruited 
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 How will patients be approached to ask them to take part? 
We will ask your staff to identify patients that meet the criteria. Then an explanation will be given 
that we would like to recruit patients to a study that uses a questionnaire to ask questions about 
their health. This will involve a once off interview and will take about 20 minutes of their time. 
Interested patients will then be given more information by the researcher and asked to sign consent. 
 
 How will data collection happen? 
The researcher will then conduct the interview if the patient has given consent. The researcher will 
hold and store the data in a locked store and will keep the personal information (e.g. name) separate 
from the questionnaire data. The patient’s name will not appear on the questionnaire which will 
only have a study number as an identifier. 
 Responsibilities of the study site 
We are asking you to assist in identifying patients who meet the study criteria and to introduce them 
to the researcher who will discuss the research with them and ask for their informed consent. We 
are also asking that should a patient become distressed during the interview that your counselling 
staff would be prepared to provide the necessary support for the participant. We have found in 
previous studies that participants welcome the opportunity to respond to questions asked in the 
Memorial Symptom Assessment Scale and that distress is infrequent. Please would you note your 
agreement to provide this support when you respond to our request to conduct research within 
your facility. 
 
 Study feedback 
 Pertinent results will be made available to the study population in lay language in the form of a 
multilingual poster to be displayed at the local HIV clinic. More detailed scientific abstract will be 
made available to all healthcare professionals and the full thesis send to the Ministry of Health. 
 
I will be the principal investigator throughout the study. Please do not hesitate to contact me should 
there be any queries at any stage of the study. I am looking forward to work with you and your staff. 
A date for the launch will be set, when ethical approval has been granted by the Ministry of Health 
and Social services as well as the UCT Research Ethics Committee, the latter can be contacted should 
there be any ethical concerns (0027-21-4066338) 
 
Yours sincerely, 
Maja Brand 
 
 
 
 
 
